Magnetic resonance imaging of intraspinal stem cell grafts: Tracking and targeted transplantation by Lamanna, Jason J.
!
Magnetic Resonance Imaging of Intraspinal Stem Cell Grafts: 
Tracking and Targeted Transplantation 
 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to 
The Academic Faculty 
 
by 
 
Jason J. Lamanna 
 
 
 
 
 
 
 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 
Department of Biomedical Engineering 
 
 
 
 
 
 
 
 
 
Georgia Institute of Technology & Emory University 
August 2015 
 
 
 
Copyright © 2015 by Jason J. Lamanna 
!
Magnetic Resonance Imaging of Intraspinal Stem Cell Grafts: 
Tracking and Targeted Transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approved by: 
 
Dr. Nicholas M. Boulis, Advisor 
Department of Neurosurgery, School of Medicine 
Emory University 
Department of Biomedical Engineering 
Georgia Institute of Technology & Emory University 
 
Dr. John N. Oshinski, Advisor 
Department of Radiology, School of Medicine 
Emory University 
Department of Biomedical Engineering 
Georgia Institute of Technology & Emory University 
 
Dr. Jacques Galipeau 
Departments of Hematology and Medical Oncology, Pediatrics, and Medicine 
School of Medicine 
Emory University 
 
Dr. Shawn Hochman 
Department of Physiology, School of Medicine 
Emory University 
Department of Biomedical Engineering 
Georgia Institute of Technology & Emory University 
 
Dr. Shella Keilholz 
Department of Biomedical Engineering 
Georgia Institute of Technology & Emory University 
 
Date!Approved:!May!11th,!2015!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
To#my#family#and#friends#
!
iv 
ACKNOWLEDGEMENTS 
 
 I would first like to acknowledge and specifically thank my mentors, Dr. John 
Oshinski and Dr. Nicholas Boulis.  Thank you for having me in the lab, developing ideas 
and experiments that formed this thesis, and for the flexibility to independently explore 
the questions addressed in this thesis.  I don’t think I could have imagined a better 
scenario for my dissertation studies and I have learned so much from you both. 
 I also must express great appreciation for my committee members, Dr. Jacques 
Galipeau, Dr. Shawn Hochman, and Dr. Shella Keilholz.  Thank you for all of the 
guidance and time put into guiding me on this journey.  I also thank you for your 
flexibility.  I would specifically like to thank Dr. Hochman for his guidance and 
enormously helpful review of my work. 
 Without the support of my colleagues in the lab, this thesis would not have been 
possible.  I would like to especially thank Dr. Juanmarco Gutierrez and Lindsey Urquia. 
Words cannot express how much time and effort they put into these projects.  Juanmarco 
contributed incalculable amounts of insight and kept me sane during the process.  
Lindsey spent at least a thousand hours working on the histology for this project.  We’re 
the three best friends that anyone could have…  I would also like to thank the others who 
devoted a lot of time and worked on these projects, including Dr. Thais Federici, Victor 
Hurtig, Dr. Jon Riley, Cheryl Moreton, and Elman Amador.  
 I am very grateful of my lab mates.  Thank you to Eleanor Donnelly, Deirdre 
O’Connor, Anthony Dosante, Jeff Mader, Jessica Emery, Annie McDonough, Luke 
Timmins, Lizz Iffrig, and Adrian Lam who all contributed to this work. 
v 
 I would also like to thank my collaborators, including Dr. Allan Kirk, Jaclyn 
Espinosa, Michael Larche, Cody Anderson, Pete Piferi, Eric Jablonoski and Andrey 
Krasnopeyev for all of their contributions. 
 I appreciate the support of all the students, faculty, and administrators at Emory 
University and Georgia Institute of Technology in the MD/PhD program and the 
Biomedical Engineering Program, specifically Mary Horton.  Special thank you to Neal 
Laxpati for all of his supervision and insight. 
 Thank you to my friends and colleagues from medical school who supported me 
in medical school and in my transition to graduate school.  Thank you Jimmy Daruwalla, 
Emily Ferrell, Phil Mitchell, Tarik Madni, Dina Itum, Max Weiss, Karl Langberg, and 
Emily Ebert for all of the good times. 
Thank you to my friends Zach Shader, Zach Levine, Dan Ludin, Jordan 
Rosenbalm, Max Tyroler, Mat Shorstein, Lina Gugucheva, Daniel Liss, Chris Akers, and 
Leslie Stockton for motivating me in this long, difficult journey.  I truly feel lucky to 
have such great friends and support. 
 Most importantly, I would like to especially thank my Mom, Dad, and Sister 
Kelly for always being there for me throughout the years.  I love you all very much and 
this would not have been possible without your love and support.  This work is dedicated 
to you. 
 This work was supported by the Amyotrophic Lateral Sclerosis Association and 
the Emory University/Georgia Institute of Technology Center for Regenerative Medicine 
and Engineering. 
 
vi 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iv 
LIST OF TABLES viii 
LIST OF FIGURES ix 
LIST OF SYMBOLS AND ABBREVIATIONS xi 
SUMMARY xiii 
CHAPTER 
1 INTRODUCTION 1 
Spine Cord Disease and Amyotrophic Lateral Sclerosis 1 
Stem Cell Therapy 2 
Stem Cell Transplantation for ALS: The Emory Experience 4 
Survival and Identification of Transplanted Cell Grafts 6 
Thesis Organization 8 
2 Objectives and Specific Aims 11 
3 Cellular Therapeutics Delivery to the Spinal Cord: Technical 
Considerations for Clinical Application 13 
Introduction 14 
Delivery Methods 15 
Future Perspectives 33 
Conclusions 37 
4 Magnetic Nanoparticle Labeling of Human Cortical Neurospheres with 
Ferumoxytol for Diagnostic Cellular Tracking 38 
Introduction 38 
Methods 41 
vii 
Results 50 
Discussion 57 
Conclusions 60 
5 Long-Term MR Tracking and Stereological Quantification of 
Ferumoxytol Labeled Human Neural Progenitor Cells Transplanted into 
the Porcine Spinal Cord 61 
Abstract 61 
Introduction 64 
Methods 66 
Results 78 
Conclusions 100 
6 Development of a Magnetic Resonance Imaging Compatible Spinal 
Injection System 103 
Introduction 103 
Materials and Methods 105 
Results 109 
Conclusions 113 
7 Magnetic Resonance Imaging-Guided Transplantation of Neural Stem 
Cells into the Porcine Spinal Cord: A Technical Note  114 
Introduction 116 
Materials and Methods 117 
Results 123 
Discussion 128 
Conclusions 130 
8 Conclusions 131 
REFERENCES 133 
VITA   147 
viii 
LIST OF TABLES 
Page!
Table!1:!Review of technical aspects in select clinical trials transplanting cells to 
the spinal cord.! 18!
Table!2:!Review of published clinical trials transplanting cells to the spinal cord.! 20!
Table!3:!Dissociated Cells: Ferumoxytol Incubation Conditions.! 43!
Table!4:!Formed Neurospheres: Ferumoxytol Incubation Conditions.! 44!
Table!5:!Passaged Neurospheres: Ferumoxytol Incubation Conditions.! 44!
Table!6:!Pig Cohorts.  ! 67!
Table!7:!Contingency table for hNPC-FLow cell grafts.! 85!
Table!8:!Contingency table for hNPC-FHigh cell grafts.! 85!
 
 
  
ix 
LIST OF FIGURES 
Page!
Figure!1:!Spinal!cord!stabilization!and!injection!system!for!intraspinal!stem!cell!
transplantation.! 5!
Figure!2:!Gross!analysis!of!male!ALS!spinal!cord.! 7!
Figure!3:!Histology!and!Immunohistochemistry!in!patient!tissue.! 8!
Figure!4:!Gamma!Microinjection!Platform.! 27!
Figure!5:!Anatomic!Targeting.! 31!
Figure!6:!Cannula!Type!Comparison.! 31!
Figure!7:!HNPC!Culture!and!Ferumoxytol!Incubation!Schematic.! 42!
Figure!8:!Incubation!of!human!cortical!neurospheres!with!ferumoxytol!
nanoparticles.! 52!
Figure!9:!Cellular!internalization!of!ferumoxytol!nanoparticles.! 54!
Figure!10:!Cell!dynamics!following!ferumoxytol!labeling.! 56!
Figure!11:!Spinal!Cord!Transplantation!Schematic.! 67!
Figure!12:!Motor!Function!Assessed!with!the!Tarlov!Scale.! 79!
Figure!13:!Preliminary!Identification!of!Ferumoxytol!Labeled!Cell!Grafts!in!
the!Porcine!Spinal!Cord.! 81!
Figure!14:!In#vivo#identification!and!tracking!of!ferumoxytolUlabeled!grafts!
(Cohort!C).! 82!
Figure!15:!In#vivo#tracking!and!quantification!of!ferumoxytolUlabeled!grafts.! 83!
Figure!16:!Representative!Micrographs!of!On!and!Off!Target!Cell!Grafts.! 84!
Figure!17:!FerumoxytolUlabeled!grafts!identified!postmortem!(28!day!cohort!B).! 88!
Figure!18:!FerumoxytolUlabeled!grafts!identified!postmortem!(42!day!cohort!C).! 90!
Figure!19:!FerumoxytolUlabeled!grafts!identified!postmortem!(105!day!cohort!D).91!
Figure!20:!Quantification!of!Transplanted!Cell!Graft!Survival!with!Stereology!
of!Human!Nuclei.! 93!
x 
Figure!21:!Quantification!of!Histological!Iron!in!Transplanted!Cell!Grafts.! 94!
Figure!22:!Correlation!Analysis!of!MR!Graft!Volume,!Histological!Iron,!and!
Cell!Survival!of!Transplanted!Human!Neural!Progenitor!Cells.! 96!
Figure!23:!Differentiation!of!FerumoxytolULabeled!Human!Neural!Progenitor!
Cells!in!the!Porcine!Spinal!Cord.! 97!
Figure!24:!In!Vivo!Transmission!Electron!Microscopy.! 98!
Figure!25:!Luxol!Fast!Blue!Staining!of!Myelination!Surrounding!Transplanted!
FerumoxytolULabeled!Cell!Grafts.!!!! 99!
Figure!26:!Surgical!Stereotactic!SpineUMounted!Injection!Platform.! 105!
Figure!27:!Overview!of!ClearPoint!System!from!MRI!Interventions.! 106!
Figure!28:!ComputedUAided!Design!Schematic!of!Prototype!MRUCompatible!
Injection!Platform.!!! 109!
Figure!29:!Custom!Built!Infusion!Needle!and!Guide!Cannula.! 110!
Figure!30:!Human!Spinal!Cord!Phantom!Model.! 111!
Figure!31:!MRUGuided!Injection!of!Ferumoxytol!Nanoparticles!into!the!Spinal!
Cord!Phantom.! 112!
Figure!32:!In!Vitro!Assessment!of!an!MRUCompatible!Spinal!Injection!System!
with!a!Phantom!Model.!!! 119!
Figure!33:!MRUGuided!Transplantation!Strategy!in!the!Porcine!Spinal!Cord.! 120!
Figure!34:!MRUCompatible!Spinal!Injection!System!Placement!and!
Targeting/Trajectory!Planning!In!Vivo.!!! 124!
Figure!35:!MRUGuided!Spinal!Cord!Transplantation!In!Vivo.!!! 126!
Figure!36:!Histological!Confirmation!of!Graft!Delivery!into!the!Spinal!Cord.! 127!
 
 
  
xi 
LIST OF ABREVIATIONS 
ALS! ! Amyotrophic!Lateral!Sclerosis!
ANOVA! ! Analysis!of!Varience!
βTIII! ! BetaUtubulin!III!
CNS! ! Central!Nervous!System!
CD! ! Cluster!of!Differentiation!
DBS! ! Deep!Brain!Stimulation!
fALS! ! Familial!Amyotrophic!Lateral!Sclerosis!
FDA! ! Food!and!Drug!Administration!
GFAP! ! Glial!Fibrillary!Acidic!Protein!
GRE! ! Gradient!Echo!
Hep! ! Heparin!
hNPC! ! Human!Neural!Progenitor!Cell!
hNPCUFHigh! High!dose!ferumoxytol!labeled!human!neural!progenitor!cell!
hNPCUFLow! Low!dose!ferumoxytol!labeled!human!neural!progenitor!cell!
HuNu! ! Human!Nucleus!
MRI! ! Magnetic!Resonance!Imaging!
MHC! ! Major!Histocompatibility!Complex!
MS! ! Multiple!Sclerosis!
NPC! ! Neural!Progenitor!Cell!
PFA! ! Paraformaldehyde!
PBS! ! Phosphate!Buffered!Saline!
pNPC! ! Pig!Neural!Progenitor!Cell!
PLO! ! PolyULUOrnithine!
xii 
PS! ! Protamine!Sulfate!
PB! ! Prussian!Blue!
SCI! ! Spinal!Cord!Injury!
SMA! ! Spinal!Muscular!Atrophy!
SPION! ! Superparamagnetic!Iron!Oxide!Nanoparticle!
T! ! Tesla!
TE! ! Echo!Time!
TEM! ! Transmission!Electron!Microscopy!
TR! ! Repetition!Time!
TSE! ! Turbo!Spin!Echo!
 
 
 
  
xiii 
SUMMARY 
Transplantation of cellular therapeutics into the spinal cord has been explored as 
treatment for a range of degenerative and traumatic diseases. The post-transplantation 
fate of cellular therapeutics is poorly understood in both large animal models and in 
human studies because of limitations in cell graft detection. A minimally invasive 
technology for cellular graft tracking to visualize grafts in vivo is needed. However, it is 
important that the diagnostic marker does not impact the engraftment or efficacy of 
transplanted cells.  We developed a straightforward, rapidly translatable method to label 
human neural progenitor/stem cells with magnetic ferumoxytol nanoparticles.  We 
investigated the potential effect of ferumoxytol labeling on biological properties of the 
cells and transplanted them into a large animal (porcine) spinal cord.  We assessed the 
feasibility and safety of in vivo diagnostic cell graft tracking using Magnetic Resonance 
Imaging and post-mortem histological identification in a clinically relevant model.  
Furthermore, we leveraged this tracking approach to develop and assess a minimally 
invasive, Magnetic Resonance Imaging-guided technique for targeted intraspinal stem 
cell graft transplantation in a large animal model. 
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CHAPTER 1 
 
 
INTRODUCTION 
The purpose of Chapter 1 is to briefly introduce the problem and setup the 
motivation for the thesis. 
 
1.1 Spinal Cord Disease and Amyotrophic Lateral Sclerosis 
Diseases of the spinal cord can arise from very diverse pathological disease 
processes, including tumorigenic, traumatic and neurodegenerative etiologies.  
Consequences include significant impairment of motor, sensory, and/or autonomic 
functions.  Furthermore, the spinal cord and surrounding structures have a complex, 
delicate organization with limited capability for self-repair.  Diseases such as traumatic 
Spinal Cord Injury (SCI) and non-traumatic conditions such as Multiple Sclerosis (MS), 
Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA) push the self-
renewing capacity of the spinal cord beyond what is feasible resulting in chronic 
impairment and a poor prognosis.  This poor prognosis is not exclusively due to the 
pathophysiology and limited capacity for repair, but also to the challenge of developing 
and delivering therapeutics to the spinal cord. 
Amyotrophic Lateral Sclerosis (ALS) is a fatal and relentlessly progressive 
neurodegenerative disease that involves death of upper motor neurons in the cerebral 
cortex/brain stem and lower motor neurons in the spinal cord.  ALS has a reported 
incidence of between 1.5 and 2.6 per 100,000 person/years among Caucasian populations 
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in Europe and North America86.  ALS constitutes a disease with highly variable clinical 
features and poor ability to predict prognosis.  Median survival after diagnosis ranges 
from 3 to 5 years40,156.  Riluzole, the only Food and Drug Administration (FDA) approved 
pharmacological treatment for ALS, has shown limited efficacy, prolonging the median 
survival of patients by only 2 to 3 months.  The disease is characterized by a progressive 
degeneration of the MNs that supply voluntary muscles, including UMNs in the cerebral 
cortex and LMNs in the spinal cord4.  The clinical presentation is heterogeneous, but the 
degeneration universally presents clinically as progressive motor weakness that leads to 
paralysis and ultimately to death, usually from respiratory failure.  ALS is considered to 
be sporadic in most cases with mutations in certain genes accounting for over half of 
familial ALS (fALS) cases29,106,119,122. Some of these genes are known to alter the onset, 
severity or progression of the disease157.  Discovery of ALS causing genetic mutations 
has not led to a breakthrough in understanding the pathogenesis of the disease.  The 
search for a common pathway for all mutations leading to degeneration is tantamount in 
developing therapeutic targets121.  Accumulation of disease causing mutant proteins and 
the neuroinflammatory reaction caused by activated glial cells are two common 
characteristics of many neurodegenerative diseases, such as ALS, Alzheimer’s and 
Parkinson’s. The discovery of these underlying mechanisms of pathogenesis and the lack 
of an effective therapy for ALS provides a unique atmosphere for the discovery of new 
pharmacological and non- pharmacological therapeutics.  
 
1.2 Stem Cell Therapy 
“Stem cell” is a term used to describe a specific cell type that has two key 
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characteristics: the capacity to differentiate to multiple cell types and the ability to 
replicate or self-renew its population.  There are many different classes of stem cells 
based on their source and differentiation capabilities.  Embryonic stem cells are termed 
pluripotent owing to their ability to differentiate into cells of all three germ layers.  Other 
stem cells, such as neuronal progenitor cells, have more limited differentiation 
capabilities and are termed multipotent.  Multipotent stem cells are innately limited to 
differentiate only into cells from the lineages from which they were derived.  Neural 
progenitor cells are limited to differentiate to either neuronal or glial cells, including 
astrocytes and oligodendrocytes. 
   Stem cells, or stem cell-derived cells, can most simply be used to replace lost 
cells such as oligodendrocytes, neurons, motor neurons, and astrocytes.  These cells may 
also provide an additional therapeutic effect by secreting trophic factors that are 
neuroprotective or that promote neuroregeneration, such as cytokines and growth factors.  
The modification of stem cells via gene therapy to produce or reduce specific factors is 
an additional level of specificity, which allows the therapeutic to target specific aspects of 
the disease under investigation.   
Restoration of motor neuron function through cellular replacement has been 
studied as a therapeutic strategy in rodent models of ALS and spinal cord injury.  
Although transplantation of neurons derived from human embryonic stem cells and 
neural stem cells has been examined in rodents,12,142,162,164 practical issues might limit the 
clinical translation of direct motor neuron replacement to humans.  
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Axonal defects, including degeneration of the neuromuscular junction and distal 
axon, are some of the earliest hallmarks of ALS, occurring before symptom onset and the 
ultimate loss of motor neurons.35  Consequences of these early defects include a loss of 
trophic support, suggesting that intraspinal transplantation of stem cells that secrete 
neurotrophic factors could be a strategy that provides a bystander mechanism of 
neuroprotection for diseased motor neurons.  Neuroprotection by growth factors has been 
studied extensively for the treatment of ALS, and vascular endothelial growth factor and 
insulin-like growth factor I (IGF-I) have been shown to provide neuroprotection in both 
in vitro and in vivo models of ALS and motor neuron degeneration.135,136 Transplantation 
of stem cells that secrete growth factors provides support for endogenous cells in the 
spinal cord microenvironment.  Cortical human neural progenitor cells engineered to 
secrete glial cell-derived neurotrophic factor (GDNF) confer motor neuron protection 
after transplantation into the spinal cords of SOD1G93A transgenic rats.148  Similarly, 
transplantation of neural progenitor cells producing either GDNF or IGF-I into SOD1G93A 
mice attenuates motor neuron loss.110  Cellular therapies might, therefore, represent a 
source of neurotrophic support for diseased motor neurons in ALS.  
 
1.3 Stem Cell Transplantation for ALS: The Emory Experience 
In September 2009, the US FDA approved the first clinical trial of human spinal 
cord stem cell (HSSC) injections into the spinal cord for the treatment of ALS 
(ClinicalTrials.gov identifier NCT01348451).  In the trial, which involved 15 patients 
with ALS, HSSCs were delivered into lumbar and/or cervical segments of the spinal cord 
using the stabilization device developed by our group (Figure 1).  In 2012, enrollment 
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was completed and surgical transplantation of all patients occurred without neurological 
complications of the procedure33,38,127,128.  The primary objective of the trial was to 
determine the feasibility, safety and toxicity of direct spinal cord transplantation of 
HSSCs into patients with ALS.  The study was designed to balance risk to participants 
with the acquisition of new knowledge regarding direct spinal cord transplantation, and 
included a sequential series of patient cohorts that fall under a ‘risk escalation’ paradigm.  
Under this paradigm, risk to patients receiving HSSC transplants escalated across the 
different cohorts according to disease severity and the number and placement of 
injections.  In 2013, the FDA approved the Phase 2 dose escalation and safety trial, which 
is currently in progress with enrollment completed (ClinicalTrials.gov identifier 
NCT01730716). 
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Figure 1. Spinal cord stabilization and injection system for intraspinal stem cell 
transplantation.  A) Platform anchored to patient’s spine allows the platform to move 
with the patient during ventilation and inadvertent patient movement preventing spinal 
cord shearing.   The two bridge rails (blue), one of which is scored at 2-mm intervals to 
aid regular positioning of injections are fixed to percutaneous spine mounted posts.  
Gondola (green) allows for adjustment in the x and y planes and correction of the sagittal 
and coronal angles of the cannula trajectory.  Mechanical Z drive (orange) allows precise 
raising and lowering of a floating cannula.   B) Cannula tip is position 1 – 2 mm medial to 
the dorsal root entry zone.  C) Needle penetrates a fixed depth into spinal cord. 4, 5, or 6 
mm tips are used depending on preoperative measurements of cord thickness.  D) Once 
needle tip is positioned at the target, metal outer sleeve is pulled up leaving flexible 
tubing exposed.  This flexibility adds further safety. 
 
1.4 Survival and Identification of Transplanted Cell Grafts 
The current ALS trial lacks a method for identifying transplanted stem cells.  The 
barriers to identifying the transplanted cells include the relatively small number of cells 
compared to the volume of the spinal cord, the typical long delay between transplantation 
and autopsy, and the inability to mark the cells by immunohistochemistry specific for 
human proteins.  We have developed the technique of matching the “fingerprint” pattern 
of spinal cord vasculature imaged live during surgery to the post-mortem tissue (Figure 
2).  Ongoing work at Emory by Dr. Jonathan Glass’ group150 has used rtPCR targeting 
donor specific Human Leukocyte Antigen (HLA) genes, as well as FISH and anti-
RBMY1A1 RNA binding protein immunohistochemistry (IHC) for Y chromosome 
markers (Figure 3).  However, the former method provides little data on the percentage 
of transplanted cells to engraft and no data on the fate of the cells.  Similarly, Y 
chromosome probe staining can only be employed in female patients.  Therefore, it has 
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proven difficult to identify the cell graft with post-mortem tissue histology, difficult to 
confirm that the graft was delivered to the appropriate location in the spinal cord, and 
difficult to track the cell graft while the patient is still alive to fully understand long-term 
effects and/or to be able to optimize protocol regimens.  These methodological gaps 
create a vulnerability to failure in ongoing and upcoming clinical trials.  The need for a 
diagnostic marker of transplanted cell grafts is apparent from our experience100. 
 
 
Figure 2.  Gross analysis of male ALS spinal cord.  Gross image of the spinal cord 
shows the cord surface at the site of Human Spinal Stem Cell transplant.  The vascular 
anatomy between intraoperative videos (A) corresponds to the post-mortem tissue (B). 
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Figure 3.  Histology and Immunohistochemistry in patient tissue.  A lower power 
view of the spinal cord.  Nest of cells located in circled region.  High power image of 
immunohistochemical staining with antibody RBMYAL, an RNA binding protein voded 
on the Y chromosome, and seen only in male cells.   
 
 
 
1.5 Thesis Organization 
 
The remainder of the thesis is as follows: 
CHAPTER 2: Objectives and specific aims.  Reviews the overall objective of the thesis in 
three specific aims.  Specific Aim 1 covers in vitro labeling of human neural progenitor 
cells with ferumoxytol nanoparticles (Chapter 4).  Specific Aim 2 assesses the ability to 
use the labeling approach from Specific Aim 1 in a large animal (porcine) model of 
spinal cord transplantation (Chapter 5).  Specific Aim 3 leverages the methods developed 
in Specific Aims 1 and 2 to develop and test a novel MRI-guided spinal cord 
transplantation device (Chapters 6 and 7). 
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CHAPTER 3: Cellular Therapeutics Delivery To The Spinal Cord: Technical 
Considerations For Clinical Application.  Dr. Miller, Dr. Riley, Victor Hurtig, Dr. 
Boulis, and I review the current state of clinical trials and techniques available for 
transplantation of cellular therapeutics into the spinal cord.  We also discuss advances in 
cellular graft tracking and image guided-delivery that will improve stem cell 
transplantation in the spinal cord.   
 
CHAPTER 4: Magnetic Nanoparticle Labeling of Human Cortical Neurospheres with 
Ferumoxytol for Diagnostic Cellular Tracking discusses the approach used to label 
clinical grade human neural progenitor cells with ferumoxytol nanoparticles for cellular 
graft tracking with MRI and assess the hypothesis that these cells can be labeled with 
ferumoxytol.  The potential in vitro adverse effects on biological function of the cells are 
analyzed. 
 
CHAPTER 5: Long-Term MR Tracking And Stereological Quantification Of 
Ferumoxytol Labeled Human Neural Progenitor Cells Transplanted Into The Porcine 
Spinal Cord applies the ferumoxytol-labeled human neural progenitor cells to a large 
animal model of spinal cord cell transplantation and assesses the hypothesis that 
ferumoxytol can be used as a diagnostic cellular marker.  The potential in vivo adverse 
effects on biological function and safety in the animal model are analyzed. 
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CHAPTER 6: Development Of A Magnetic Resonance Imaging Compatible Spinal 
Injection System overviews development of a MRI-compatible injection platform and 
development of a system capable of conducting MRI-guided transplantation of cellular 
therapeutics into the spinal cord. 
 
CHAPTER 7: Minimally Invasive Magnetic Resonance Imaging-Guided Transplantation 
Of Human Neural Stem Cells Into The Porcine Spinal Cord.  Lindsey Urquia, Victor 
Hurtig, Dr. Gutierrez, Cody Anderson, Pete Piferi, Dr. Federici, Dr. Oshinski, Dr. Boulis, 
and I test the hypothesis that cellular therapeutics can be transplanted into the spinal cord 
of a large animal under the guidance of MRI. 
 
CHAPTER 8: Conclusions. I conclude the thesis by discussing the implications of this 
work, possible clinical translation, and future directions.   
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CHAPTER 2 
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!
OBJECTIVES AND SPECIFIC AIMS 
Transplantation of cellular therapeutics to the spinal cord is a promising treatment option 
for patients with neurodegenerative and traumatic diseases of the spinal cord.  However, 
ongoing clinical trials have limited evidence confirming successful graft delivery and no 
histopathological evidence of graft survival.  These limitations complicate the assessment 
of clinical outcomes and determination of therapeutic efficacy. The aim of this thesis is to 
develop and validate a methodology to address these key limitations.  We will label 
human neural progenitor cells in vitro with the Super-Paramagnetic Iron Oxide 
Nanoparticle (SPION) ferumoxytol.  This method will allow non-invasive cell graft 
tracking in vivo with Magnetic Resonance Imaging (MRI) and post-mortem histological 
identification in our large animal (porcine) model.  This approach will aim to allow 
clinicians to better understand the fate of transplanted cell grafts. The overall goals of 
this proposal are (1) to label human neural progenitor cells with the MR contrast agent 
ferumoxytol, (2) to evaluate the effects of ferumoxytol labeling, and (3) to assess the 
clinical utility in a large animal spinal cord.  Successful completion of this would 
enable MR-guided approaches to spinal cord cell transplantation.  In order to do so, we 
propose the following specific aims:  
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1. Develop and evaluate a method to label human neural progenitor cells 
cultured as free-floating neurospheres with ferumoxytol nanoparticles.  This 
aim consists of the following sub-aims: 
 
a. Develop a protocol to enable stem cells grown in cortical neurospheres 
to internalize ferumoxytol 
b. Quantify the efficiency of ferumoxytol internalization and MRI 
contrast produced 
c. Evaluate the effects of ferumoxytol labeling on cell viability and 
functionality 
2. Assess the ability to visualize ferumoxytol-labeled cells in a large animal 
(porcine) spinal cord model of cell transplantation using MRI. To evaluate the 
clinical utility of employing ferumoxytol-labeled cell grafts for visualization and 
tracking, we must transplant cells in to a large animal spinal cord. We propose 
three sub-aims. 
 
a. Identify the location and quantify the size of transplanted 
ferumoxytol-labeled cell grafts in vivo, over time using MRI 
b. Correlate MR images of ferumoxytol-labeled grafts to histological 
quantification of cell engraftment and iron deposition 
c. Evaluate the effects of ferumoxytol labeling on in vivo cell graft 
dynamics 
3. Develop a minimally invasive, MR-guided method for intraspinal cell 
transplantation.  This aim consists of the following sub-aims: 
 
a. Develop an MR-compatible spine-mounted device capable of MR-
guided intraspinal cell graft transplantation 
b. Test the MR-guided intraspinal transplantation device in vitro using a 
spinal cord phantom model 
c. Assess in vivo feasibility of the MR-guided transplantation system in a 
large animal (porcine) spinal cord using ferumoxytol-labeled cells 
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CHAPTER 3 
 
 
CELLULAR THERAPEUTICS DELIVERY TO THE SPINAL CORD: 
TECHNICAL CONSIDERATIONS FOR CLINICAL APPLICATION* 
 
Current literature demonstrates the efficacy of cell-based therapeutics in small animal 
models of varied spinal cord diseases.  However, logistic challenges remain towards 
development of an optimized delivery approach to the human spinal cord.  Clinical trials 
utilize a variety of methods to achieve this aim.  In this chapter, I review currently 
employed delivery methods, compare the merits of alternate delivery paradigms, 
introduce their implementation in completed and ongoing clinical trials, and discuss 
promising near-term advances in image-guided delivery and in vivo graft tracking. 
 
 
 
 
 
 
 
* Lamanna JJ, Miller JH, Riley JP, Hurtig CV, Boulis NM. Cellular Therapeutics 
Delivery to the Spinal Cord: Technical Considerations for Clinical Application. 
Therapeutic Delivery. 2013;4(11). 1397- 410. 
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3.1 INTRODUCTION 
The human spinal cord is complex and has a limited capacity for self-repair.  This 
holds true for both spinal cord injury (SCI) and non-traumatic conditions such as 
Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular 
Atrophy (SMA).  There remain no clinically proven effective treatment options for 
patients with SCI aside from stabilization and supportive measures 49,124,131.  The most 
recent traumatic SCI guidelines provide only Class III evidence for hemodynamic 
support to an elevated mean arterial pressure of 85-90 mmHg 131.  Further, ALS and 
SMA remain as insidious and fatal neurodegenerative diseases without adequate 
pharmacologic treatments.  Recent literature supports a considerable interest in clinical 
translation of cellular therapeutics as possible disease modifying agents given preclinical 
efficacy data69. To this end, multiple putative cellular therapeutics have undergone 
clinical investigation, as illustrated in Table 1 and Table 2.  However, an understanding 
of the factors necessary to achieve optimal graft delivery and the technology necessary to 
achieve this goal continue to undergo evolutionary advancements. 
Current strategies to deliver cellular therapeutics to the spinal cord include local 
and intravascular delivery approaches.  Local administration may be achieved through 
either direct cellular injection into the spinal cord parenchyma or through intrathecal 
delivery into the subarachnoid space.  Each approach is associated with advantages and 
drawbacks.  The pathology being treated, constraints inherent to the delivery approach, 
and limitations of current technology must be considered.  The broadened future 
translation of cellular therapeutics will be hastened by continued evolutionary 
improvements to current delivery methods and associated technologies.  This manuscript 
! 15!
will review the above mentioned delivery methods with an emphasis on advantages and 
limitations, introduce recently completed and ongoing clinical trials in the context of the 
delivery approaches employed, and describe near term advancements that promise to 
improve current generation cell graft delivery methods. 
 
3.2 DELIVERY METHODS 
Two primary routes may be considered for delivery of cellular therapeutics to the spinal 
cord: local or intravascular administration.  When broadening a discussion to gene-based 
therapeutic approaches, peripheral delivery with retrograde axonal transport is an 
additional option.  Retrograde axonal transport is not suitable for delivery of cellular 
therapeutics.  Intravascular approaches may include both intra-arterial and intravenous 
routes while local administration may be achieved by either intraparenchymal or 
intrathecal injection.  Each delivery strategy has inherent benefits and limitations which 
must be considered in the context of both the pathology being treated and the specific 
therapeutic goals.  Route-specific factors to consider include:  1) obtainable anatomic 
specificity, 2) desired graft distribution, 3) tolerable degree of invasiveness to deliver 
therapy, and 4) implications for immunologic sensitization. 
Previous groups have directly compared intravenous, intrathecal, and 
intraparenchymal methodologies for transplanting cells to the spinal cord in rodents 
5,6,77,105,112,141,158.  In a rodent model of SCI, the engraftment efficiency of Mesenchymal 
Stem Cells (MSCs) transplanted with direct intraparenchymal injection to the lesion site 
(6.1%) was greater than both intrathecal (3.4%) and intravenous approaches (1.6%) 21 
days after transplantation112. However, the results from this study are difficult to interpret 
! 16!
as the delivered dose was not consistent between transplantation methods, with more 
cells delivered with the intrathecal and intravascular approaches.  Takahashi and 
colleagues compared different methods of administering neural stem/progenitor cells to 
treat SCI in mice and tracked the cell grafts for 42 days in vivo using a bioluminescence 
imaging reporter gene strategy 152.  The same delivered dose (5 x 105 cells / 2 µL) was 
maintained for all groups undergoing transplantation via the intravenous, intrathecal, or 
intraparenchymal route.  The intraparenchymal approach had the greatest engraftment 
efficiency with numerous differentiated cells within the injured parenchyma.  With the 
intrathecal approach, few grafted cells were located on the surface of the lesion site and 
on other areas of uninjured spinal cord.  The engrafted cells differentiated into neurons, 
astrocytes, and oligodendrocytes as well.    With both of these approaches, cells were not 
found engrafted at off-target sites, outside of the spinal cord.  In the intravenous 
transplant group, cells were not engrafted at the injury site or spinal cord, but rather 
located in the lung, spleen, and kidney.  Furthermore, several mice in the intravenous 
group died shortly after transplantation due to likely pulmonary embolism. The 
longitudinal bioluminescence imaging results showed a similar pattern of graft survival, 
with the most signal loss or cell death occurring in the first week after transplantation.  
These results do not account for possible improved homing of alternate cell types.  
However, with the given cell type, the intraparenchymal approach improved engraftment 
efficiency, targeting to the injured site, and reduced procedural-associated complications, 
when the delivered dose is held constant152.  The utility of in vivo graft tracking methods 
is also apparent in this study. 
! 17!
Below, preclinical and clinical data separately exploring the utility of each 
approach is discussed.  An exhaustive discussion of the homing capacity of different cell 
types for intravascular and intrathecal delivery approaches is outside the scope of this 
manuscript and is not discussed in detail.  Clinical data for technical considerations of 
transplantation in select ongoing and completed clinical trials are provided Table 1. 
Greater detail is given to intraparenchymal delivery due to the wide variety of inherent 
technical considerations associated with this approach. An expanded list of published 
clinical trials and associated adverse events are provided Table 2.  A direct comparison 
between adverse events of individual trials and cell delivery approaches is confounded by 
inherent differences in: 1) expected adverse events, 2) trial design methodologies, 3) 
patient populations, 4) regulatory oversight, 5) data collection, and 6) quality assurance. 
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3.2.1 Intravascular Delivery 
Vascular-mediated cellular therapeutics delivery has been trialed for a variety of 
non-neurologic treatment endpoints48,113,160.  Cells delivered to the spinal cord through an 
intravenous or intra-arterial route must bypass the blood brain barrier (BBB).  Therefore, 
vascular-mediated cellular delivery relies entirely upon the CNS-homing capabilities of 
an introduced cell type, with additional considerations including the dose and rate of 
delivery.  Preclinical small animal studies have supported the capability of MSCs to 
support remyelination2,50 with other unpublished reports of improvement following SCI 
in small animal models118. 
The primary advantage of intravascular delivery is the use of a minimally invasive 
approach.  Disadvantages of this delivery method include the concern for tumorigenesis of a 
systemically delivered cell type and vascular complications associated with bulk cell delivery 
(e.g. pulmonary embolism). Pulmonary embolism has been observed in small animal studies 
with high rate delivery of elevated quantities of cellular grafts likely indicating bulk 
sequestration within the pulmonary vasculature37.  This effect is reported to be absent with 
lower quantities of administered cells and when high doses are given at a lower rate of 
administration118.  While methods of follow-up have varied widely, neither observation of 
tumorigenesis nor of vascular-related complications of cell administration have been reported 
to date in clinical trials22,25,62,102,118.  Adverse events from published clinical trials are 
provided in Table 2.  While small animal studies and initial clinical usage appear to 
demonstrate the achievable safety with this approach, detailed analysis of the results of 
intravascular cell delivery is complicated by multiple factors.  These include: 1) a lack of 
data in large animal studies (e.g. biodistribution scaling studies or attempts to demonstrate 
! 23!
efficacy), 2) variability in the cell types administered between studies, 3) inconsistent 
attempts to document cellular homing in small animal and clinical studies, 4) the lack of a 
control arm in the performed clinical studies, and 5) significant variability in the manner of 
post-intervention follow-up. 
 
3.2.2 Intrathecal Delivery 
Intrathecal cell delivery to the spinal cord is accomplished through access to the 
subarachnoid space in an approach that is technically identical to a lumbar puncture.  
Protocols have described delivery in either a single session or fractionated over multiple 
injection procedures with some using concomitant intrathecal steroid injections to reduce 
the risk of aseptic meningitis.  Advantages to an intrathecal approach include 
concentration of graft delivery adjacent to the neuraxis and the use of a minimally 
invasive approach.  Possible disadvantages include the risk of developing meningitis 
from the injection procedure (aseptic or bacterial), immunologic activation, and a risk of 
disseminated tumorigenesis from injected cellular grafts.  The actual risks of these 
outcomes will be forthcoming as additional trial results are published.  However, adverse 
events from published clinical trials are provided in Table 2. 
Similar to intravascular cellular therapeutics delivery, some preclinical data 
supports cellular ‘homing’ to the site of interest, as briefly discussed above.  Support for 
a cellular homing capability through the subarachnoid space is best supported in small 
animal SCI studies.  This homing capacity, although not seen in all preclinical small 
animal studies 152, has been observed to be restricted to the lesion site and adjacent 
tissue6,21,77,137.  Cellular homing has also been explored in a large animal (canine) study.  
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Intrathecal delivery of autologous and allogeneic MSCs in an experimental model of SCI 
supported migration and engraftment of both to the injury site54.  Despite a ‘homing 
capability’, the majority of injected cells have been documented to remain in the 
intrathecal space in preclinical studies of SCI101 and ALS47.  Thus, apart from safety 
considerations, it is unclear how to choose the dose (graft cell number) given the limited 
penetration of cord parenchyma.  Furthermore, variability in observed penetration creates 
a significant hurdle for translation of these approaches. 
While no domestic reports have yet been published on the clinical application of 
intrathecal delivery, the international literature indicates that cellular grafts have been 
delivered for the treatment of cerebral palsy117,159, ALS62,116, MS62,  and SCI15,16,85.  
While rigorous interpretation of these results is complicated by multiple factors, they 
provide pilot data as to the lack of tumorigenicity and overall safety profile that may be 
achieved with intrathecal cell-based administration.  Additionally, two clinical studies 
have attempted to categorize radiographic biodistribution of labeled cells.  Callera et 
al15,16 attempted to provide radiographic support for cell delivery and engraftment at a 
site of SCI.  The authors demonstrated a cohort-specific hypointensity at the lesion site in 
patients that received autologous CD34+ bone marrow cells labeled with magnetic 
nanoparticles.  Karussis et al 62 labeled a subset of enrolled trial patients that had ALS 
and MS with ferumoxides, superparamagnetic iron oxide nanoparticles (SPIONP), visible 
on Magnetic Resonance Imaging (MRI).  The authors reported diffuse radiographic 
evidence of cells within the parenchyma, meninges, and at the ventral/dorsal root entry 
zones.  However, no histopathology was available, so the actual engraftment efficiency 
represented by this MRI signal is unclear.  Continued development of radiographic 
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markers for cellular homing and an improved understanding for the mechanistic basis of 
cellular homing will be critical to the further clinical development of intrathecal cellular 
delivery.  Ongoing and completed clinical protocols for intrathecal cellular graft delivery 
are summarized in Table 1 & Table 2. 
 
3.2.3 Intraparenchymal Microinjection 
Direct microinjection into the spinal cord represents the most conceptually 
straightforward but technically involved delivery paradigm.  This process requires 
exposure of the spinal cord at the level of interest followed by targeting, cannulation, and 
graft injection.  Advantages of a direct microinjection delivery paradigm include the 
ability to deliver cellular grafts with anatomic specificity as well as to precisely titrate the 
dose at the target site.  However, this anatomic specificity constrains the utility of this 
approach when treating anatomically diffuse disorders (e.g. ALS, SMA).  Potential 
disadvantages include the morbidity that may occur with: surgical exposure, spinal cord 
cannulation/infusion into the spinal cord, and tissue injury from immunologic rejection of 
cellular grafts in the spinal cord.  Notable adverse events of trials published to date are 
summarized in Table 2.  While several of the listed adverse events are expected of the 
surgical approach (e.g. incisional pain, pseudomeningocele), the possible sequelae of 
both the approach and intraparenchymal microinjection process appear to be mainly 
transient.  Multiple factors must be considered when utilizing a direct microinjection 
approach, including:  1) cannula stabilization technique, 2) targeting methodology, 3) 
cannula type, and 4) infusion parameters. 
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3.2.3.1 Direct Microinjection Approach Considerations 
Cannula stabilization techniques range from non-stabilized (freehand) to fully 
stabilized approaches.  Stabilized techniques may further be divided into patient-
stabilized and non-patient stabilized approaches.  Much of the literature exploring the 
delivery of cellular therapeutics for various spinal cord afflictions in small animal disease 
models utilized a non-stabilized approach in which a microinjection needle was used to 
cannulate the spinal cord by hand with the volume and rate manually controlled by the 
surgeon or assistant.  Stabilized approaches to cell delivery provide the ability to 
precisely target single or multiple sites within the spinal cord with a reduced concern for 
iatrogenic SCI.  Further, stabilized approaches allow for the timed infusion of a graft 
while using a pre-programmed delivery pump.  Patient-stabilized delivery approaches are 
anchored relative to the patient’s anatomy (e.g. spinal elements) whereas non-patient 
stabilized approaches are held immobile relative to an alternate point of reference (e.g. 
operating room table).  In our experience, patient stabilized approaches appear to reduce 
the risk of inadvertent movement of the spinal cord relative to the microinjection cannula 
that may occur from expected (e.g. cardioballistic, cardiorespiratory) or inadvertent (e.g. 
iatrogenic) spinal cord movement129.  Figure 4 A-D demonstrates an example of a patient 
stabilized microinjection platform, the most recent iteration of the platform utilized by 
our group.  It is respectively shown disassembled and assembled in Figure 4 A, B.  
Figure 1C demonstrates a thoracolumbar approach in a preclinical large animal (swine) 
with self-retaining retractor blades in place and stabilizing posts rostral and caudal to the 
incision.  Figure 4 D shows the fully assembled platform with microinjector and 
microinjection cannula in place after completion of laminectomy and dural opening. 
! 27!
 
Figure 4: Gamma Microinjection Platform.  A)  (Far left)  The laminar bone screws 
are shown with associated nuts.  (Far right)  sheaths and spacers for bone screws.  (Right, 
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Left)  Self-retaining retractors with four holes for alignment with translaminar 
screws/sheaths and platform rail system.  (Top)  Two of four required retractor arms and 
blades.  (Far Bottom)  Tunnelers to dock laminar screw sheaths on lamina prior to screw 
introduction.  (Bottom)  Gondola platform to mount microinjector platform on platform 
rail system.  (Center)  Platform rail system and microinjector.  B)  In situ demonstration 
of γ-platform without attached retractor arms/blades.  C)  In vivo demonstration of 
gamma platform prior to laminectomy and before attachment of gondola or microinjector 
platform.  D)  In vivo demonstration of fully assembled microinjection platform.                  
* Reproduced with Permission from this reference130. 
 
 
Current methodologies for targeting cellular grafts to the spinal cord include 
freehand injection based upon knowledge of internal spinal cord anatomy, the use of 
microelectrode recording, and the use of anatomic (coordinate-based) microinjection.  
The use of intraoperative imaging-based graft delivery is a possible future targeting 
approach that is discussed later in this review.  Freehand targeting has been used in both 
preclinical small animal studies and in international clinical settings.  Concerns with this 
approach include inconsistently reproducible accuracy to the target and precision between 
injections when considering multiple targets.  Our group has employed both 
microelectrode recording- and coordinate-based targeting strategies125,126.  Both 
approaches utilize an understanding of the cross-sectional anatomy of the spinal cord.  A 
schematic view of the spinal cord is shown in Figure 5.  Microelectrode recording is used 
in a capacity similar to deep brain stimulation.  As the microelectrode is passed into the 
spinal cord, the audible and visible waveform differs between white and grey matter.  
Disadvantages of this approach include a need to rigidly cannulate the spinal cord and the 
possible need to make multiple passes with the microelectrode.  In our early preclinical 
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experiences, this resulted in an elevated early post-surgical morbidity profile.  The 
coordinate-based technique utilizes external landmarks to interpolate the coordinates for 
intraspinal microinjection targets.  Identification of the dorsal root entry zone (DREZ) 
has proven a reliable surface landmark by which to target sites of interest within the 
spinal cord.  Following target cannulation, infusion is undertaken at predefined volume 
and rate infusion parameters.  Figure 5 provides a schematic representation of how our 
group utilizes this technique to target the ventral horn in both a preclinical and clinical 
setting.  A reproducible depth is maintained by incorporation of a flange at a known 
distance from the needle tip, as shown in Figure 6.  We have previously used a Z drive 
with a micrometer attached to measure the depth of penetration.  However, the cord tends 
to be compressed by the needle passing through the pia, confounding depth 
measurements.  This phenomenon generally results in an underestimate of penetration 
depth resulting in targeting deeper than the intended target. 
In the experience of our group, the single greatest impact upon morbidity 
reduction in preclinical studies has been observed through advancements in cannula 
design.  Figure 6 A, B illustrates a comparison between a rigid and floating cannula.  The 
floating cannula has a beveled tip to ease penetration through the pia and a flange at a 
known distance from the microinjection needle tip.  The latter allows accuracy to a 
desired depth, and depth precision when comparing serial individual injections.  The 
floating cannula is introduced into the spinal cord in rigid confirmation.  Once depth is 
reached and the flange is flush to cord surface, the rigid outer cannula is retracted.  This 
is demonstrated in Figure 6 C.  This allows the floating cannula to accommodate 
pronounced spinal cord excursion that occurs with patient ventilation, cardioballistic cord 
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pulsation, and inadvertent patient movement/injection hardware manipulation.  In 
addition to stabilizing the floating cannula tip, the flange may also act to retard reflux by 
capping the penetration site.  Cannula design-based efforts to minimize reflux in cranial 
cell delivery applications have attempted through the use of either a stepped cannula 
design 66 or the use of a curved ‘steerable’ cannula 115.  In cranial applications, the latter 
is reported to have significant reductions in infusate reflux compared to straight cannula 
administration.  This may be both because the injection apparatus incorporates a stepped 
design and that the steerable needle prevents a line of site trajectory between the 
parenchymal surface and the target. 
The set of chosen infusion parameters is also crucial towards optimizing both the 
delivered dose and engraftment efficiency.  Number of injections, infusion rate, infusion 
volume, reflux prevention (cannula held in tissue for a time after cell infusion), and the 
quantity of cells delivered comprise the relevant factors.  Manipulation of these factors 
can impact observed reflux, graft viability, and local tissue trauma associated with graft 
delivery.  Elevated rate, volume, and delivered dose may overcome the capability of the 
graft site to accommodate the graft and may also result in local injury.  Additionally, an 
elevated injection rate may compromise graft viability through both increased velocity 
and a shearing effect observed within the microinjection cannula 1,115,154.  Finally, a 
threshold effect may be observed in the local graft environment above which elevated 
graft density can result in diminished graft viability143.  Infusion parameters implemented 
in current and recently completed clinical trials are in summarized in Table 1. 
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Figure 5: Anatomic Targeting.  A schematic is provided demonstrating the use of the 
dorsal root entry zone as a targeting landmark.  The microinjection needle is translated 1-
2mm medially to accommodate for pial vascularity. * Reproduced with Permission from 
this reference127. 
 
 
 
Figure 6: Cannula Type Comparison.  A comparison of rigid and floating cannulas is 
provided.  A)  A  29-gauge stainless steel stepped rigid cannula (top) is shown adjacent to 
two floating cannulas (middle, bottom).   The floating cannulas are shown in rigid 
conformation.  Floating cannulas with 4mm (middle) and 3mm (bottom) fixed needle tips 
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are shown. B)  In this panel, the outer rigid cannula has been retracted.  Flexible silastic 
tubing is shown.  The flange at the base of the needle prevents overpenetration.  The 
longer proximal flange (bottom) aids in orthogonal spinal cord penetration while the 
more heavily tapered bevel (bottom) aids in pial penetration.  C) The floating cannula is 
introduced into the spinal cord in rigid conformation.  After pentration to the appropriate 
depth, using a preselected needle of desired length, the rigid outer cannula is 
retracted.  The flexible silastic tubing is then capable of maintaining positional stability 
with cardioballistic and ventilation-associated spinal cord movement. * Reproduced with 
Permission from this reference130 
 
3.2.3.2 Direct Microinjection Trial Summary & Future Directions 
A selected review of completed and ongoing direct delivery clinical trials is 
provided in Table 1 with additional completed trials listed in Table 2.  While each listed 
trial was completed for the treatment of ALS or SCI, they varied widely with respect to 
graft cell type, stabilization method, targeting approach, dose delivered, and infusion 
parameters.  All of the published works cited in Table 2 did not provide consistent 
evidence of a prospective, controlled design with concomitant uniform recording of 
outcome measures. 
The limited published data generally appear to support the safety achievable with 
direct cellular microinjection into the spinal cord.  Data driven assessments regarding the 
superiority of specific targeting approaches, stabilization methods, cellular dosages, and 
infusion parameters in ALS and SCI will be forthcoming upon the conclusion of the 
current generation of clinical trials.  Consideration of immunosuppression, largely outside 
of the scope of this manuscript, holds an uncertain future and is being evaluated in at 
least some of the trials in Table 1 and Table 2. 
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3.3 FUTURE PERSPECTIVES 
3.3.1 In Vivo Cell Graft Tracking 
A critical issue faced in translating cell therapy from the bench to bedside is 
confirming the delivered dose and engraftment efficiency of cell grafts.  Calculating dose 
certainty and engraftment efficiency depends on quantifying delivered and surviving graft 
cells at the target site.  The delivered dose is affected by the delivery method, targeting 
accuracy, reflux from the tissue, and the quantity of cells delivered.  Engraftment 
efficiency is dependent on survival, migration, and rejection by the immune system.  In 
animal models, calculating dose and engraftment efficiency is easily achieved with post-
mortem immunohistochemistry.  Species-specific antibodies can be used to identify cell 
grafts when the donor and the recipient are of a different species.  Post-mortem graft 
identification with histological methods in human patients has proved challenging due to 
the low number of engrafted cells and the limited methods for differentiating donor and 
recipient cells of the same species.  Furthermore, post-mortem dose calculation only 
gives data from a single time point.  The initial delivered dose cannot be calculated and 
longitudinal observations cannot be made.  This critical issue highlights the need for a 
method to track cell grafts in vivo.  Cells can be genetically modified to express reporter 
genes to improve graft identification and produce image contrast, but this is an invasive 
method that has consequences on cell function, toxicity, and immune response67,83.  
Moreover, such a label would complicate the regulatory approval process by altering the 
therapeutic biological product.  Cells can also be labeled ex vivo, prior to transplantation, 
with a physical particle for identification.  The cell internalizes the particles, but the 
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particle concentration can either be diluted with cellular divisions or internalized by host 
cells78.   
Many different approaches have been employed to label cellular grafts for in vivo 
tracking.  Reporter gene systems have been designed for bioluminescence imaging147, 
optical imaging11, MRI84,167, positron emission tomography (PET)56,79, and near infrared 
imaging93.  A PET reporter gene system was used to track cytotoxic T lymphocytes 
implanted in to the brain of a patient with Grade IV glioblastoma multiforme163.  This 
was the first domestic, published reporter gene-based imaging method used to track 
implanted cells in vivo in humans.  However, the limitation of the reporter gene approach 
is the risk associated with the random integration of reporter transgenes from viral 
vectors.  This is considered an invasive approach.  Additionally, the intensity of the 
signal produced by the reporter gene has been limited in some approaches.  Methods of 
physically labeling stem cells ex vivo, prior to transplantation, have been used to track 
stem cells in vivo.  These approaches include superparamagnetic iron oxide nanoparticles 
(SPINOP) for visualization with MRI39,46 and radionuclides for PET.  SPIONPs are FDA-
approved for imaging contrast and are manufactured in the US.  Additionally, they have 
been safely and effectively used outside of the US to track stem cell grafts in several 
clinical trials 27,155, including healthy controls123, and trials in the central nervous 
system15,62,166.  However, caution must be taken to:  1) confirm the cells internalized the 
particles, 2) calculate the contrast produced, and 3) characterize the effect the SPIONPs 
have on cell viability, function, and differentiation.  For a full review on assessing the 
cytotoxicity of cells labeled with SPIONPs, please see this review144. 
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While limitations exist in current methods for tracking cell grafts in vivo and 
identifying them post-mortem, determining delivered cell dose, confirming targeting 
accuracy, and calculating engraftment efficiency is essential for the successful translation 
of cellular therapeutics.  SPIONP-labeled cells can be used to determine the initial 
location and dose of delivered cells and to track the cell graft longitudinally.  
Determining the initial graft location in the spinal cord can have a significant impact on 
expected graft survival, as grey and white mater have been shown to have different 
patterns of immune response95.  Additionally, it may be possible to use SPIONPs to 
identify donor cells post-mortem107.  SPIONP-labeled cell therapies may be used in 
upcoming clinical trials because of: 1) SPIONP FDA approval for different indications, 
2) a clinical precedent with use in clinical trials, 3) a less invasive approach than reporter 
gene systems and PET tracers, and 4) definitive in vitro and in vivo evidence of unaltered 
cell properties can be collected as part of the pre-clinical data package for individual cell 
therapies before clinical use.  Regardless, developing a reliable method for calculating 
delivered dose, the initial graft location, and engraftment efficiency is essential for 
widespread translation of cellular therapeutics in the spinal cord. 
 
3.3.2 Image-Guided Delivery 
Although the currently employed methods of direct intraparenchymal injection 
are reliable and safe, future approaches utilizing image-guidance for targeting and 
delivery could provide less invasive, more accurate methods to transplant cells into the 
spinal cord.  Advanced intraoperative image-guided techniques offer an approach for 
improved direct targeting while percutaneous transplantation offers reduced 
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periprocedural inflammation and scarring.  Computed Tomography (CT) and MRI have 
been used in the clinic for many years to guide percutaneous cordotomy 
procedures57,58,94, and intraoperative MRI has been employed in surgical procedures in 
and around the spinal cord30,104.  Furthermore, percutaneous transplant of a cellular graft 
to the canine spinal cord has been achieved under fluoroscopic guidance74.  
MRI is unparalleled in its spatial resolution and ability to visualize anatomy and 
pathology in the spinal cord, drastically improving targeting accuracy.  Intraoperative 
MR targeting, trajectory planning, and cannula guidance are well established in the brain 
for the implantation of deep brain stimulation electrodes72,88,146.  Sub-millimeter accuracy 
in placement of electrodes has been achieved with this MR-guided approach72.  To 
translate MR-guided placement to the spinal cord, modifications to the current generation 
of platforms and cannulas are necessary.  Extensive preclinical studies in large animal 
models must be conducted to evaluate the safety and accuracy of percutaneous, MR-
guided spinal cord cell graft transplantation. Delivering cells percutaneously eliminates 
the need for an open surgical procedure.  However, it raises other concerns, including: 1) 
cerebrospinal fluid leakage from needle puncture of the dura mater, 2) hemorrhage of 
spinal cord blood vessels from incidental needle puncture, 3) inaccurate targeting due to 
displacement of the cord from the resistance of the dura mater to needle puncture, 4) 
limited range of transplantation sites due to the vertebra, and 5) potential damage to the 
cord from needle puncture.  While these concerns must be addressed before translation to 
the clinic, MR-guided delivery of stem cells to the cord remains particularly promising. 
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3.4 CONCLUSIONS 
Cell-based therapies targeting varied spinal cord pathologies have proved efficacy 
in small animal models, feasibility in large animal studies, and safety in domestic and 
international clinical trials. The key to the successful, widespread clinical translation of 
cellular therapeutics is multi-faceted, including the optimization of: 1) patient selection, 
2) cell line, 3) target site, and 4) delivery method.  Intravascular, intrathecal, and 
intraparenchymal approaches offer distinct advantages/limitations and have been 
explored in the clinical setting.  Future technical evolutionary advancements in delivery 
and tracking must occur to further optimize delivery of cellular therapeutics to the spinal 
cord. 
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CHAPTER 4 
 
 
MAGNETIC NANOPARTICLE LABELING OF HUMAN CORTICAL 
NEUROSPHERES WITH FERUMOXYTOL FOR DIAGNOSTIC CELLULAR 
TRACKING 
(SPECIFIC AIM 1) 
 
4.1 INTRODUCTION 
Stem cell transplantation is a promising therapeutic strategy to overcome the 
regenerative limitations of the central nervous system (CNS).  The aim is to replenish 
neuronal tissue and execute neuroprotective functions to counteract predominant 
degeneration caused by CNS pathologies such as amyotrophic lateral sclerosis (ALS), 
spinal cord injury (SCI), and multiple sclerosis 17,63,82,98.  Currently, clinical trials for 
ALS, SCI, and Parkinson’s disease are ongoing and emerging evidence indicates that this 
approach is safe, feasible, and may have therapeutic effects 33,52,60,97,109.  The next step is 
to focus on ensuring accuracy and confirming delivered cell dosage to study the 
effectiveness of this approach.  Therefore, it is critical to develop dynamic, non-invasive 
imaging technologies that may track cell graft delivery over time.  The ability to localize 
cell engraftments in the clinic may also be used to assess cell distribution, differentiation, 
and viability to optimize treatment regimes45.  
The use of super paramagnetic iron oxide nanoparticles (SPION) has been 
validated as an imaging modality for tracking neural progenitor cells (NPC) using 
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MRI8,19.  In animal models, cells are usually labeled using transfecting agents or reporter 
genes, but these techniques are difficult to use in humans due to overt complications that 
may arise.  Novel labeling and optimization techniques need be developed to improve 
gradual signal disappearance and reduce cell toxicity103.  Studies using simple SPION 
labeling for dissociated human neural stem cells show limited effect on cells’ viability, 
tumor tropism, and lineage differentiation8,19,26,51,140.  Most of these studies have 
employed nanoparticles that are not FDA approved or used Fedirex IV SPION, which has 
been discontinued in the United States19. 
This study aims to provide critical data on our ability to label human Neural 
Progenitor Cells (hNPCs) with ferumoxytol nanoparticles for diagnostic cellular tracking 
with MRI.  Ferumoxytol is a SPION approved for clinical use by the US FDA as an 
intravenously administered MRI contrast agent.  Currently, ferumoxytol is the only 
particle approved by the FDA and manufactured under Good Manufacturing Practice 
conditions.  Ferumoxytol is a nanoparticle with an iron oxide core and a carboxydextran 
coat with a diameter of approximately 15 nanometers.  The iron oxide core creates 
inhomogeneities in the local magnetic field, which can be detected with MRI, and 
provides a unique histological target for identifying grafted cells.  We propose to use 
ferumoxytol “off label” as a cellular diagnostic marker to track transplanted cell grafts in 
the spinal cord with MRI.  While the field of molecular imaging has employed SPION for 
cellular tracking, few clinical-grade human cell lines have been employed and limited 
data is available in the spinal cord. Furthermore, it is critical to rigorously establish safe 
labeling conditions and establish potential cytotoxicity for individual cell lines.  Thus, the 
present study will help us define safe and effective ferumoxytol labeling conditions. 
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 Currently there are only limited methods of identifying transplanted cell grafts, 
either in vivo or post-mortem, in clinical trials.  This creates an unacceptable risk for 
failure because the investigators are unable to determine cell delivery, engraftment, 
migration, or survival.  Potential therapeutic efficacy is difficult to attribute to the 
transplanted cells, as there is no diagnostic marker monitoring the therapy.  SPION cell 
labeling with ferumoxytol for diagnostic monitoring of transplanted cell grafts provides a 
rapidly translatable method to identify in vivo and post-mortem the location of the 
transplanted graft.  This will give insights in to delivery location, engraftment, survival, 
and potentially migration. 
The aim of this study is to label a human cell line cultured as cortical 
neurospheres with ferumoxytol nanoparticles.  Previous studies using SPION for 
molecular imaging have mostly employed non-human cell lines in monolayer culture 
systems.  Neurospheres culture presents a unique problem in terms of cell access to 
SPION in the culture media, as effective ferumoxytol labeling requires most cells to 
internalize the particles.  In monolayer culture systems, nearly all cells can directly access 
the media.  However, only cells on the surface of the sphere will be able to directly 
access the media in a neurosphere culture system.  This could create a heterogeneous 
population of labeled and unlabeled cells, complicating our ability to accurately track 
transplanted cell grafts.  This methodological complication is relevant because many 
human neural stem cell lines are cultured as neurospheres. 
We hypothesize that ferumoxytol can be internalized by hNPCs without 
significant cytotoxicity and produce adequate contrast for cellular tracking with MRI.  
The novel aspects of this aim pertain to the use of a clinical-grade human neural stem cell 
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line and the method it is cultured (cortical neurospheres).  Limited studies have been 
performed on clinical-grade cell lines utilizing SPION with well-defined safety profiles.  
We aim to determine the optimal method for labeling hNPCs cultured as cortical 
neurospheres with ferumoxytol nanoparticles and to rigorously characterize the potential 
cytotoxic effects of labeling hNPCs with ferumoxytol with multiple independent assays 
quantifying viability, function, antigenicity, and the amount of internalized ferumoxytol.  
These studies present the possibility of generating a rapidly translatable approach for 
diagnostic cell tracking to large animal models and clinical studies. 
 
4.2 METHODS 
4.2.1 Human Neural Progenitor Cell Culture 
Frozen stocks of early passage 21 hNPCs were graciously provided by the Clive 
Svendsen laboratory at Cedars-Sinai Regenerative Medicine Institute64,149.  The hNPCs 
were originally isolated from eight-week-old postmortem fetal cortex of an aborted fetus 
with Institutional Review Board approval.  Briefly, the intact cortical mantel was isolated 
and dissociated to a single cell suspension.  The resulting cell line was expanded to free 
floating neurospheres of hNPCs and at passage 21 were frozen and sent to Emory 
University for the following studies.   
The hNPCs were thawed and maintained as free floating neurospheres in T75 
tissue culture flasks maintained with Neural Stem Cell Medium (Stemline Neural Stem 
Cell Expansion Medium, S3194, Sigma-Aldrich) supplemented with recombinant human 
Leukemia Inhibitory Factor (10 ng/mL, LIF1010, EMD Millipore), recombinant human 
Epidermal Growth Factor (100 ng/mL, GF003-AF, EMD Millipore), and 
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antimicrobial/bacterial reagent (15240062, Invitrogen) [Maintenance Medium].  The cells 
were cultured in a standard cell culture incubator at 37 °C and 5% CO2.  When the 
diameter of >75% of the neurospheres exceeded 500 micrometers, the neurospheres were 
passaged by mechanical sectioning31.  Briefly, one flask of neurospheres were isolated 
from the media, placed in a plastic petri dish, orthogonally sectioned with an automatic 
tissue chopper (McIlwain Tissue Chopper, Lafayette Instrument Co.), and split in to two 
flasks with 50% fresh and 50% used maintenance media.  The resulting clumps of cells 
reform spheres over the course of several days.  The spheres were passaged 
approximately every eight days and 50% of the maintenance media was replaced with 
fresh maintenance media every 4 days.  To prepare for transplantation and cytotoxicity 
assays, the neurospheres were chemically dissociated with trypsin (TrypeLE Express 1X, 
11965092, Invitrogen) and DNAse (D4527, Sigma-Aldrich) and filtered with a 50 micron 
separation filter (130-041-407 Miltenyi Biotech) to a single cell suspension in 
Magnesium and Calcium free hibernation medium (Proprietary, provided by Svendsen 
lab).  The cells were concentrated to 10,000 cells/µL and stored on ice.  Cells between 
passage 25 and 35 were used for the labeling experiments on the same day of dissociation 
(Figure 7). 
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Figure 7. hNPC Culture and Ferumoxytol Incubation Schematic.  Representative 
schematic of hNPC cultured from neurospheres, mechanical passage, neurospheres 
growth, and dissociation to single cells.  The ferumoxytol nanoparticle were introduced to 
the cell culture medium at different time points. 
 
4.2.2 Ferumoxytol Labeling of Human Neural Progenitor Cells   
Three different strategies were employed to systematically induce hNPCs to 
internalize the ferumoxytol nanoparticles (Figure 7).  The first was to incubate 
dissociated cells, ready for transplantation, with increasing concentrations ferumoxytol in 
different conditions.  The length of incubation, incubation media used, and the addition of 
transfection agents heparin (Hep) and/or protamine sulfate (PS) were all employed as 
outlined in Table 3.  24 hours was chosen as the maximum time point because of 
temporal viability limitations after dissociation.  Transfection agents are charged reagents 
that potentially increase the efficiency of ferumoxytol internalization18,153.  Two different 
incubation media were chosen because the neurospheres are cultured in maintenance 
medium, but transplanted as dissociated cells in hibernation medium. 
 
Table 3: Dissociated Cells: Ferumoxytol Incubation Conditions 
Incubation 
Medium 
Ferumoxytol [µg/mL] Time 
(hours) 
PS [µg/mL] / Hep 
[IU/mL] 
Hibernation 0, 100, 200, 400, or 
1000 
6, 12, or 24 0 
Maintenance 
Hibernation 
50 or 400 12 
60 / 2 or 10 / 0, 
respectively Maintenance 
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The second approach was to incubate pre-formed neurospheres, four to six days 
after passage, with increasing concentration of ferumoxytol as outlined in Table 4.  The 
third was to incubate neurospheres with increasing concentrations of ferumoxytol for 
seven days immediately following mechanical passage (Table 5).  At this time point, 
only small clumps remain and the neurospheres form over the course of several days.  For 
all conditions, neurospheres were dissociated seven days after passage.  Prior to 
dissociation, the neurospheres were washed twice with Dulbecco’s Modified Eagle 
Medium and then after dissociation the cells were washed twice with hibernation medium 
to remove extracellular ferumoxytol nanoparticles.   
 
Table 4: Formed Neurospheres: Ferumoxytol Incubation Conditions 
Post-Passage 
Day 
Ferumoxytol [µg/mL] Time 
(hours) 
PS [µg/mL] / Hep [IU/mL] 
6 0, 100, 200, 400, or 
1000 
24 0 
5 
48 0 
50 or 400 48 60 / 2 or 10 / 0, respectively 
 
 
Table 5: Passaged Neurospheres: Ferumoxytol Incubation Conditions 
Post-Passage 
Day 
Ferumoxytol [µg/mL] Time 
(hours) 
PS [µg/mL] / Hep [IU/mL] 
0 
0, 100, 200, 400, or 
1000 168 
0 
50 or 400 60 / 2 or 10 / 0, respectively 
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4.2.3 Rapid Assessment of Ferumoxytol Labeling 
To rapidly assess the efficiency and effects of ferumoxytol uptake (labeling) for 
each of the different conditions, a viability assay and an in vitro MRI were performed.  
These assays were performed immediately following washing and dissociation.  Cell 
viability was calculated using a trypan blue exclusion assay to measure live/dead cells on 
a hemocytometer under a microscope.   
To assess the MRI contrast of the labeled cells, 250,000 cells in a pellet in a 
microcentrifuge tube were placed in a water bath in a 32-channel head radiofrequency 
coil in a Siemens 3T Trio Trim Full-Body MR scanner.  The effect of the cells on the MR 
images contrast was calculated by determining the volume of the T2* signal generated by 
the cell pellet.  A gradient echo (GRE) T2*-weighted sequence sensitive to magnetic field 
inhomogeneities was utilized [multiple echo time = 10 and 16 msec, pulse repetition time 
= 788 msec, number signal average = 4, field of view = 160 x 160 mm, matrix = 512 x 
512, and slice thickness = 1.5mm)]. The two conditions that maximized MR contrast 
produced with optimal viability were chosen for further evaluation for potential 
cytotoxicity.  Control (unlabeled) cells were evaluated further as a control. 
 
4.2.4 Cellular MR Contrast Quantification 
For the two optimal labeled cell conditions and the unlabeled cells, the following 
assays were performed to establish the amount of ferumoxytol internalized and evaluate 
any potential side effects of the ferumoxytol uptake. 
MRI contrast was evaluated in the same system as section 4.2.3 (cell pellet in a 
microcentrifuge tube at 3T MRI).  However, the scans were done in triplicate and MRI 
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contrast produced was measured in a quantitative method by calculating the Signal-to-
Noise Ratio (SNR) of the cell pellet.  Groups were compared with ANOVA and 
individual t tests (p < 0.05). 
 
4.2.5 Ferumoxytol Internalization and Quantification 
Ferumoxytol nanoparticle uptake/internalization by the cells was confirmed via 
microscopy.  Immediately following labeling and dissociation, the cells were placed in 
Stemline Neural Stem Cell Medium supplemented with B-27 (17504044, Invitrogen) and 
antimicrobial/bacterial reagent (Invitrogen) [Plate Down Medium].  The cells in plate 
down medium were concentrated to 1,000 cells/µL and 40 µL of cells placed on ground 
glass coverslips coated with Poly-L-Ornithine (PLO) (P4638, Sigma Aldrich) and 
laminin (L2020, Sigma Aldrich) in 24 well tissue culture plates.  The plates were placed 
in the incubator at 37 °C and 5% CO2.  After 1 hour, the wells were flooded with an 
additional 1 mL of plate down medium.  After 24 hours, an aliquot of the cell-containing 
coverslips were fixed with 4% Paraformaldehyde (PFA) and washed three times with 
Phosphate Buffered Saline (PBS).  The coverslips were then incubated with Hydrochloric 
Acid (2% solution) and Potassium Ferrocyanide (4% solution) for Perl’s Prussian Blue 
(PB) histochemistry (CY005, Fisher Scientific).  The Perl’s reagent reacts with Iron in 
the ferumoxytol particles to generate histological blue precipitates.  Nuclear Fast Red 
background stain was used to visualize the nuclei.  The percentage of labeled cells with 
cytoplasmic Iron was calculated with ImageJ cell counter using a standard threshold for 
blue.  Cells with threshold positive blue precipitates in the cytoplasm were considered 
“labeled”.  These experiments were done in triplicate and five slips/experiment/condition 
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were analyzed.  Groups were compared with ANOVA and individual t tests (p < 0.05). 
 
4.2.6 Transmission Electron Microscopy 
A separate aliquot of cell-containing coverslips was fixed with glutaraldehyde and 
embedded in epon resin. The resin containing cells was sectioned at a thickness of 50 
nanometeres.  The sections were attached to a wire matrix and imaged with a JEOL JEM-
1210 Transmission Electron Microscopy (TEM) to determine the intracellular location of 
the ferumoxytol nanoparticles. 
 
4.2.7 Colorimetric Quantification of Cellular Iron 
To quantify the amount of intracellular ferumoxytol, a Perl’s colorimetric assay of 
Iron concentration was performed14.  Briefly, aliquots of cells were lysed and mineralized 
with high concentration hydrochloric acid.  Then the Perl’s reagent was added to generate 
a blue solution, with color dependent on Iron concentration.  The solutions were placed in 
96 well plates and the absorbance of light at 630 nm was measured with an automated 
plate reader.  The absorption of light from the cell samples was compared to a standard 
concentration curve of ferumoxytol particles.  The absorbance of the cell sample was 
normalized to unlabeled cells and plotted on the standard curve to reveal the amount of 
Iron from ferumoxytol particles in individual cells (pico-grams per cell).  Groups were 
compared with ANOVA and individual t tests (p < 0.05). 
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4.2.8 Cellular Viability Assays 
Three separate assays were performed to accurately characterize the viability of 
the labeled cells.  The trypan blue exclusion assay, as described earlier, was done five 
times for all groups.  The trypan blue assay measures membrane permeability.   
Quantitative flow cytometry live/dead staining (Life Technologies L34957) measuring 
membrane integrity was performed on recently dissociated cells.  The samples were run 
on the LSRFortessa flow cytometer.  Gating and quantification was performed using 
FlowJo software.  
An 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
colorimetric assay (MTT Cell Growth Assay Kit, CT02, EMD Millipore) measuring 
mitochondrial metabolism was performed in duplicate on cells attached to coated 
coverslips for 24 hours.  Cells were incubated with MTT agent for an additional 24 hours.  
Metabolically activate cells cleave MTT to create a byproduct with a different color 
absorption spectrum.  After 48 hours, an expression agent was added to media and 
absorbance at 630 nm was measured for each coverslip (3 coverslips/condition).  Groups 
were compared with ANOVA and individual t tests (p < 0.05). 
 
4.2.9 Cellular Differentiation 
To assess the differentiation capacity of labeled hNPCs, cells were placed on 
glass coverslips as previously described and incubated for an additional 7 days.  50% of 
the plate down media was replaced after 3 days.  The coverslips were fixed with 4% PFA 
and prepared for immuncytochemistry. Briefly, the coverslips were washed with PBS, 
incubated in blocking buffer (PBST, 5% goat serum, 5% horse serum), and placed 
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directly in primary antibodies anti-Glial Fibrillary Acidic Protein (GFAP) [1:250, Sigma 
F0382] and anti-β-tubulin III (βTIII) [1:500, Sigma T8660] overnight at 4 °C.  The slips 
were washed and placed in secondary antibodies goat-anti-rabbit Alexa-Fluor 594 
(1:1000, A11037, Invitrogen) and goat-anti-mouse 488 (1:1000, A11001, Invitrogen) for 
one hour at room temperature. The coverslips were washed with PBS and mounted in 
vectashild with 4',6-diamidino-2-phenylindole (DAPI).  The slips were visualized with a 
Nikon E400 Fluorescent microscope.  Images of five High Power Fields at 40x were 
acquired.  The percentage of GFAP+ (astrocytic differentiation) and βTIII+ (neuronal 
differentiation) cells for each condition was quantified using ImageJ cell counter.  Three 
coverslips per condition performed in duplicate.  Groups were compared with ANOVA 
and individual t tests (p < 0.05). 
 
4.2.10 Cellular Antigenicity 
As an estimate of potential increased antigenicity of ferumoxytol labeled cells, 
flow cytometry quantification of antigenic surface markers were quantified and compared 
to control cells.   The cells were processed with the following antibodies: anti-Human 
Leukocyte Antigen (HLA)-DR APC (BD Biosciences 340549), anti-β2 microglobulin 
FITC (BD Biosciences 551338), anti-CD80 PE (BD Biosciences 560925), and anti CD86 
PE (BD Biosciences 560957).  The samples were run on the LSRFortessa flow 
cytometer.  Gating and quantification was performed using FlowJo software.  
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4.3 RESULTS 
4.3.1 Preliminary Studies on Ferumoxytol Labeling Methods 
The first method of ferumoxytol labeling studies involved dissociated hNPCs.  
While the viability was relatively unaffected, all labeling conditions had limited uptake of 
ferumoxytol nanoparticles.  Furthermore, with the longer incubation times, the amount of 
cells “recovered” after labeling was significantly less than the amount of cells initially 
incubated.  Uptake of ferumoxytol by pre-formed neurospheres occurred, but at a low 
level.  The incubation with ferumoxytol did not alter cell viability or change the 
morphology of the neurospheres.  All conditions incubated with heparin showed 
significant decreases in viability and impaired neurospheres formation with no increase in 
labeling efficiency.  The conditions incubated with protamine sulfate showed no change 
in viability or labeling efficiency.  Finally, the conditions incubated with ferumoxytol 
immediately following mechanical passage showed significant particle uptake and little 
change in cell viability.  These incubation conditions were explored further. 
 
4.3.2 Ferumoxytol Dose Escalation 
The passaged neurospheres had sufficient uptake of ferumoxytol nanoparticles.  
To properly assess optimal incubation concentration, a dose escalation paradigm was 
used. The growing spheres were incubated for 7 days (to reach dissociation size for 
transplantation) with a 50% fresh media change occurring at post passage day 4.  The 
ferumoxytol labeling conditions did not alter neurospheres formation and were not toxic 
to the cells after dissociation, as measured by the trypan blue assay.  With increased 
ferumoxytol concentration, no significant difference (ANOVA p > 0.05, individual t tests 
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p > 0.05) in viability measured by trypan blue was observed between different 
concentrations of ferumoxytol (Figure 8 A).  However, 50 µg/mL ferumoxytol, 60 
µg/mL protamine sulfate and 2 IU/mL heparin was toxic to the neurospheres and 
excluded from analysis.  The spheres dissolved in this condition and further analysis was 
not performed. 
The contrast produced by the labeled cells was observed in vitro with MRI and 
quantified.  The strong negative contrast produced by the labeled cells is best observed 
with gradient echo sequences (T2*).  A dose-dependent increase in contrast (ANOVA p < 
0.0001) was observed (Figure 8 B, C).  The 400 µg/mL ferumoxytol and 10 µg/mL 
protamine sulfate condition was excluded from analysis because it provided no 
improvement in cell viability or MR contrast over [400 µg/mL] ferumoxytol alone.  A 
statistically significant increase in contrast was observed between the 100 and 200 µg/mL 
conditions (p < 0.05).  The difference between the 400 and 1000 µg/mL was non-
significant (p >0.05).  Based on these observations and viability measurements, the 
passaged neurospheres incubated with 200 (hNPC-FLow) and 400 (hNPC-FHigh) µg/mL 
ferumoxytol for seven days immediately following mechanical passage were chosen for 
further evaluation.   
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Figure 8. Incubation of human cortical neurospheres with ferumoxytol 
nanoparticles.  Human neural progenitor cells cultured as free floating neurospheres 
were incubated with increasing concentrations [0 – 1000 µg/mL] of ferumoxytol 
nanoparticles for 7 days.  Following incubation, the neurospheres were washed and 
chemically dissociated to a single cell suspension (A).  No significant change in cell 
viability assessed by trypan blue exclusion assay was observed with increased 
ferumoxytol concentrations (B).  Microcentrifuge tubes with a 2.5x106 cell pellet were 
immersed in water and imaged with a gradient echo T2*-weighted sequence on a clinical 
3T Magnetic Resonance Imaging scanner.  Representative images show a signal void in 
the region of the cell pellet produced by ferumoxytol (C).  The signal-to-noise ratio 
(SNR) for the volume of the cell pellet was calculated and a dose-dependent decrease in 
SNR was observed with increased ferumoxytol concentrations (D).  A significant 
difference was observed between [100 µg/mL] and [200] conditions.  No significant 
difference was observed between [200] and [400].  Ordinary one-way ANOVA and 
individual unpaired t-tests were performed (n = 5 / group).  *Significant, P < 0.05; 
**Significant, P < 0.005; ***Significant, P < 0.0005.  Graphs displayed as mean ± SD. 
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4.3.3 Ferumoxytol Particle Internalization 
HNPCs labeled with 200 and 400 µg/mL ferumoxytol [(hNPC-FLow) and (hNPC-
FHigh), respectively) and unlabeled hNPCs (0 µg/mL ferumoxytol) cells were plated on 
glass coverslips for 24 hours were evaluated for the internalization of ferumoxytol 
nanoparticles.  An aliquot of coverslips stained with the Prussian blue reagent with 
nuclear fast red background were analyzed for the presence of ferumoxytol “labeled” 
cells with characteristic perinuclear blue precipitates in the cytoplasm.  High-powered 
field micrographs show numerous labeled cells in both hNPC-FLow and hNPC-FHigh cells 
but not in unlabeled hNPCs (Figure 9 A - C).  Quantification of labeled cells with 
ImageJ minimum threshold method of cytoplasmic blue precipitates yields 53.3% of 
hNPC-FLow and 77.2% of hNPC-FHigh cells were labeled, which was a significant increase 
over unlabeled hNPCs (ANOVA, p < 0.005) (Figure 9 D).  Furthermore, the increase in 
labeling between hNPC-FLow and hNPC-FHigh was significant (p < 0.005).   
Transmission Electron Microscopy (TEM) micrographs of both hNPC-FLow and 
hNPC-FHigh cells showed abundant endosomes and lysosomes laden with 10 - 20 nm 
ferumoxytol nanoparticles (Figure 9 E - G).  Nanoparticles were confined to intracellular 
structures and not observed on the cell membrane or in the extracellular space.  
Furthermore, the internal architecture of the cells was consistently healthy with ample 
mitochondria, organelles, and neurites observed.  Control hNPCs contained few 
lysosomes or endosomes and they did not contain nanoparticles.   
The cellular concentration of iron from ferumoxytol nanoparticles was calculated 
using a PB colorimetric digestion assay.  A statistically significant difference was 
observed between all groups (p = 0.005) with 1.46 and 2.82 ρg ferumoxytol iron/cell for 
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hNPC-FLow and hNPC-FHigh cells, respectively (Figure 9H).  The intracellular iron was 
normalized to unlabeled cells, revealing only iron from ferumoxytol nanoparticles and 
excluding physiologic cellular iron. 
 
 
Figure 9. Cellular internalization of ferumoxytol nanoparticles.  Representative light 
microscopy images of cytochemical staining for cellular iron with Prussian Blue (PB) for 
unlabeled hNPCs (A), hNPC-FLow (B), and hNPC-FHigh (C) labeled cells are shown.  
Characteristic blue precipitates of iron oxide nanoparticles were observed in the 
cytoplasm of ferumoxytol-labeled cells.  A statistically significant difference was 
observed between all groups with 53.3% and 77.2% of hNPC-FLow and hNPC-FHigh cells 
labeled, respectively (D).  Transmission Electron Microscopy of hNPC-FLow and hNPC-
FHigh cells (E) revealed numerous iron-laden, electron-dense endosomes (F) containing 
nanoparticles (G).  The cellular concentration of iron from ferumoxytol nanoparticles was 
calculated using a PB colorimetric digestion assay.  A significant difference was 
observed with 1.46 and 2.82 ρg iron/cell for hNPC-FLow and hNPC-FHigh, respectively 
(H).  Scale bars: (A – C) 10 µm; (E) 3 µm; (F) 0.3 µm; and (G) 50 nm.  Ordinary one-
way ANOVA and individual unpaired t-tests were performed (n = 5 / group).  
*Significant, P < 0.05; **Significant, P < 0.005; ***Significant, P < 0.0005.  hNPC, 
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human neural progenitor cell; F, ferumoxytol; PB, Prussian Blue.  Graphs displayed as 
mean ± SD. 
 
4.3.4 In Vitro Cellular Dynamics 
Ferumoxytol labeled hNPC-FLow and hNPC-FHigh cells, and unlabeled hNPCs 
were plated on glass coverslips for 7 days for evaluation of cellular differentiation of 
attached neural progenitor cells.  Representative micrographs of unlabeled hNPCs, 
hNPC-FLow and hNPC-FHigh cells (Figure 10 A – C) show numerous GFAP+ astrocytes 
(red) and βTIII+ neuronal cells (green).  The morphology of the differentiated cells is 
similar between groups.  Quantification of differentiation reveals a statistically significant 
decrease in neuronal differentiation (35.0% hNPC, 30.0% hNPC-FLow, 21.5% hNPC-
FHigh, ANOVA p < 0.005) (Figure 10 D) with a concurrent statistically significant 
increase in astrocytic differentiation (64.6% hNPC, 70.0% hNPC-FLow, 78.5% hNPC-
FHigh, ANOVA p <0.005) (Figure 10 E).  However, a non-significant difference was 
observed between hNPCs and hNPC-FLow for differentiation to neuronal cells (p > 0.05) 
and astrocytes (p > 0.05). Total differentiation was greater than 99% of cells for all 
conditions.  Furthermore, the cellular morphology of the differentiated cells appears 
unchanged between groups. 
Trypan blue exclusion assay of cell viability between hNPC, hNPC-FLow and 
hNPC-FHigh showed no difference (Figure 10 F). Flow cytometry live/dead staining was 
used as an independent measure of cell viability and cell membrane integrity.  hNPC-FLow 
and hNPC-FHigh tended to be smaller (decreased forward scatter) and more granular 
(increased side scatter) than unlabeled hNPCs.  Viability was calculated at 92.5% hNPC, 
83.2% hNPC-FLow, and 83.3% hNPC-FHigh (Figure 10 G).   
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MTT mitochondrial metabolism assay showed a significant increase (ANOVA p < 0.005) 
in metabolism between groups (Figure 10 H).  The difference remained significant 
between all groups (p < 0.05).  Metabolism was significantly greater and normalized to 
dead, unlabeled cells. 
Analysis of cell surface antigens HLA-DR (Figure 10 I), β2 microglobulin 
(Figure 10 J), CD80 (not shown), and CD86 (Figure 10 K) with flow cytometry 
quantification revealed no change in expression between labeled and unlabeled cells.  
Furthermore, all cell types expressed Major Histocompatibility Complex (MHC) 1 (β2 
microglobulin) and MHC II (HLA-DR) proteins, but not co-stimulatory CD80/86 
antigens. 
 
 
Figure 10.  Cell dynamics following ferumoxytol labeling.  Representative images of 
immunohistochemical staining of unlabeled hNPC (A), hNPC-FLow (B), and hNPC-FHigh 
(C) labeled cells expressing the astrocytic marker GFAP (red) and the neuronal marker 
βT3 (green).  Five high power fields (40X) were analyzed for each of five coverslips 
from each condition.  A significant decrease in neuronal differentiation was observed 
between hNPC-FLow and hNPC-FHigh conditions, but not between unlabeled hNPC and 
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hNPC-FLow (D).  A concurrent, significant increase in astrocytic differentiation was 
observed (E).  Trypan Blue exclusion assay (F) and flow cytometry live/dead stain with 
AquaBlue (G) showed no change in cell viability across groups.  MTT cellular 
metabolism assay showed a significant increase in cellular metabolism with ferumoxytol 
labeling (H).  No change was observed in expression of cellular antigens Beta-2 
microglobulin (I), HLA-DR (J), or co-stimulatory molecules CD80 (now shown) and 
CD86 (K).  Scale bars: (A – C) 10 µm.  Ordinary one-way ANOVA and individual 
unpaired t-tests were performed.  *Significant, P < 0.05; **Significant, P < 0.005; 
***Significant, P < 0.0005.  hNPC, human neural progenitor cell; F, ferumoxytol; GFAP, 
glial fibrillary acidic protein; βT3, Beta Tubulin III; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; HLA, Human Leukocyte Antigen; CD, Cluster of 
Differentiation.  Graphs displayed as mean ± SD. 
 
4.4 DISCUSSION 
Sufficient uptake of ferumoxytol nanoparticles with cellular internalization was 
observed with ferumoxytol nanoparticle incubation for seven days immediately following 
mechanical passage of clinical grade human neural progenitor cells.  A dose escalation 
study revealed two conditions ([200] and [400] µg/mL ferumoxytol incubation; hNPC-
FLow and hNPC-FHigh cells, respectively) that produced adequate cellular MR contrast 
without significantly altering cell viability. The uptake of ferumoxytol particles from the 
extracellular environment is most likely achieved by active processes requiring 
endocytosis76.  Following mechanical passage, the small clumps of cells remain stable 
with cell-to-cell contact, are metabolically active, replicating, and reforming 
neurospheres.  In this time they are most likely actively sampling their environment, 
leading to increased uptake of ferumoxytol nanoparticles.  Furthermore, it is possible that 
slight membrane damage increases permeability and the ability of ferumoxytol particles 
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to enter the cell.  The small clumps of cells render this approach spatially advantageous.  
The long incubation time also renders this approach temporally advantageous to 
increased particle uptake.  Previous studies have employed much shorter incubation times 
and lower concentrations of nanoparticles to achieve cellular labeling with SPION.  
However, the cell culture system used in this study proved unique in that the cells were 
both non-adherent and non-phagocytic.  Adherent cell lines cultured in monolayer allow 
easy access of all cells in culture to the incubated nanoparticles, resulting in much shorter 
incubation times and nanoparticle concentrations20,114,145,153.  Phagocytic cells also reduce 
the time and amount of particles required because they are more actively sampling their 
environment13. 
Dissociated cells in hibernate medium are dormant and those in maintenance 
medium are unstable, attempting to regain cell to cell contain by reforming neurospheres.  
Both situations are not conductive to active environmental sampling and particle uptake.  
Furthermore, incubation of pre-formed neurospheres proved insufficient.  The failure of 
this approach was most likely due to heterogeneous labeling of cells where those on the 
surface had adequate uptake and those in the center had none.  The ferumoxytol 
nanoparticles were unable to penetrate the large neurospheres. 
Particle uptake and intracellular location in endosomes/lysosomes was confirmed 
with histochemistry and TEM.  The localization of particles in organelles suggests an 
active endocytic mechanism of uptake.  53.3% of hNPC-FLow and 77.2% of hNPC-FHigh 
cells were labeled with ferumoxytol.  While the percentage of labeled cells is lower, the 
amount of internalized ferumoxytol (1.46 and 2.82 ρg ferumoxytol, respectively) is 
similar to previously published reports45,153.  The difference in percentage of labeled cells 
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could be explained by the different histochemical approach used in our study.  The 
previous reports used a DAB enhanced Prussian blue stain with a higher sensitivity than 
standard Prussian blue staining used in our study145.   
Biosafety and unaltered cellular features are essential to the successful translation 
of diagnostic molecular imaging approaches.  In this study, we employed multiple, 
independent measures of cellular dynamics to assess potential effects of ferumoxytol 
labeling.  The differentiation of neural progenitor cells to terminal cell types (neurons and 
astrocytes) changed with ferumoxytol labeling.  A decrease in neuronal differentiation 
was observed with a concurrent increase in astrocytic differentiation.  However, the 
difference between the unlabeled hNPCs and hNPC-FLow cells was not significant with 
this sample size.  Furthermore, the primary objective of this cell line is to generate 
astrocytes for trophic support of motor neurons41.  The change in differentiation should 
not have an effect on the overall therapy. 
Cell viability calculated by flow cytometry live/dead staining and MTT assay for 
mitochondrial metabolism showed little change in viability.  The increased metabolism of 
the labeled cells observed with the MTT assay has been previously described in the 
literature145.  This change is most likely due to the increased metabolism resulting from 
the excess cellular Iron or from the ferumoxytol particles themselves altering the 
absorbance of light in the assay. 
Analysis of cellular surface antigens revealed an interesting pattern of expression 
in the hNPCs.  The cells possess both MHC I and MHC II antigens, which suggests the 
cells are capable of directly presenting antigens to the immune system.  Expression of 
MHC antigens on human neural stem cells is previously described96.  However, the cells 
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do not express co-stimulatory CD80 or CD86 molecules so they are unable to directly 
active T lymphocytes.  Importantly, the expression of these surface antigens is not altered 
by the ferumoxytol labeling approach employed in this study. 
 
4.5 CONCLUSIONS 
The present study developed a straightforward, rapidly translatable incubation 
method to label clinical grade human neural progenitor cells with ferumoxytol 
nanoparticles for diagnostic cellular imaging.  The method does not use transfection 
agents and employs an FDA approved clinical nanoparticle.  Minimal adverse effects on 
the biological properties of the ferumoxytol labeled cells were observed.   
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CHAPTER 5 
 
LONG-TERM MR TRACKING AND STEREOLOGICAL QUANTIFICATION 
OF FERUMOXYTOL LABELED HUMAN NEURAL PROGENITOR CELLS 
TRANSPLANTED INTO THE PORCINE SPINAL CORD* 
(SPECIFIC AIM 2) 
 
 
5.1 ABSTRACT 
Transplantation of stem cells into the spinal cord has been explored as treatment 
for a range of diseases. The post-transplantation fate of cellular therapeutics is poorly 
understood in both large animal models and in human studies because of limitations in 
cell graft detection. A minimally invasive technology for cellular graft tracking to 
visualize grafts in vivo is needed. However, it is important that the diagnostic marker 
does not impact engraftment of transplanted cells. We report on surgical transplantation 
of ferumoxytol labeled human neural progenitor cells into the spinal cord of a large 
animal with in vivo MRI graft tracking, quantification of cell engraftment post-mortem, 
and preliminary MR-guided delivery. 
 
Human neural progenitor cells were labeled with multiple concentrations of 
ferumoxytol ([0], [200], and [400 µg/mL]). For each of the three labeling conditions, four 
250,000 cell grafts (n=12 grafts/pig) were transplanted into the ventral horn of the 
thoracolumbar spinal cord of minipigs via direct intraspinal microinjection using a spine-
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mounted platform following laminectomy. No post-operative deficits were observed and 
the pigs were maintained for 28 (n=3 pigs), 42 (n=3), and 105 days (n=5) after surgery. 
All [200] and [400] transplanted cell grafts (n=88) were visualized in vivo with 3T full-
body MRI using a T2*-weighted gradient echo sequence 14 days after transplantation. 
63.6% of grafts were ‘on target’ in the ventral horn. The grafts were tracked 
longitudinally with serial MRI and signal intensity quantified with a minimum threshold 
method. The mean volume after transplantation was 2.3 and 13.9 µL for [200] and [400] 
grafts. Furthermore, 75% of [200] and 100% of [400] grafts were identified at post-
operative day 105 with a mean volume of 1.1 and 9.6 µL. 
 
The pigs were sacrificed and the spinal cords harvested. The cords were sectioned 
at 50 µm intervals and every 6th section immunostained for the human nucleus (HuNu). 
The engraftment of individual cell grafts was quantified using stereology for the 42-day 
cohort. The engraftment was calculated for [0] (mean 24.0% cell engraftment, range of 
0.0-65.7%), [200] (17.1, 1.0-35.9), and [400] (25.0, 0.0-45.6) and no statistically 
significant difference was observed. Degradation of MR signal between 14 and 28 days 
for [200] and [400] grafts correlated with graft survival (r=0.47, p=0.02) in the 42-day 
cohort. Stereology is ongoing for the other cohorts. Prussian Blue-HuNu co-staining and 
transmission electron microscopy of tissue sections confirmed the presence of 
intracellular iron deposits. 
 
Ferumoxytol labeling allows for immediate and long-term identification of cell 
grafts in vivo with MRI without impacting cell engraftment in a large animal xenograft 
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model. The ferumoxytol nanoparticles were observed in the cytoplasm of transplanted, 
labeled cells. This approach has the potential to be used in ongoing and upcoming clinical 
trials to monitor cell-based therapies.  Furthermore, ferumoxytol labeling allows for 
immediate visualization of stem cells transplanted into the spinal cord percutaneously 
under MR-guidance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Lamanna JJ, Gutierrez J, Urquia L, Federici T, Oshinski J, Boulis N.  Long-term MR 
tracking and stereological quantification of ferumoxytol labeled human neural progenitor 
cells transplanted into the porcine spinal cord.  World Molecular Imaging Congress 2014 
(Honolulu, September 2015).   
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5.2 INTRODUCTION 
Transplantation of stem cells into the spinal cord has been explored is a promising 
therapeutic strategy to overcome the regenerative limitations of the central nervous 
system (CNS).  The aim of stem cell therapy is both neuroregeneration and 
neuroprotection to counteract degeneration caused by CNS pathologies such as 
amyotrophic lateral sclerosis (ALS), spinal cord injury (SCI), and multiple sclerosis (MS) 
17,63,82,98.  Clinical trials for ALS, SCI, and MS are ongoing and emerging evidence 
indicates that this approach is safe, feasible, and may have therapeutic effects 33,52,60,97,109.  
To properly assess the therapeutic efficacy of these early-stage therapies, it is essential to 
confirm the accuracy of the transplantation site, the delivered dose, and the survival of 
the cellular therapeutic in vivo.  Therefore, it is critical to develop diagnostic, non-
invasive imaging technologies that may track the cell graft over time in vivo and identify 
the graft post-mortem in histological sections.  However, it is essential that the diagnostic 
marker does not impact the survival or biological properties of transplanted cells. 
Previous groups have employed super paramagnetic iron oxide nanoparticles 
(SPION) as a diagnostic marker for tracking transplanted cellular therapeutics using 
Magnetic Resonance Imaging (MRI)8,19.  Studies have shown that SPION labeling of 
human neural stem cells has limited effect on its biological properties8,19,26,51,140. Most of 
these studies have employed nanoparticles that are not currently approved by the Food 
and Drug Administration or manufactured in the United States19.  Furthermore, most of 
these in vivo studies were conducted in the CNS of a small animal model, limiting its 
ability to predict clinical utility9,39,46,107. 
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The only SPION currently FDA approved and manufactured is ferumoxytol.  
Ferumoxytol is an ultra-small nanoparticle with an iron oxide core and a carboxydextran 
coat with a diameter of approximately 15 nanometers.  While several studies have 
investigated the use of ferumoxytol as a cell label, no studies have been published in the 
CNS of a large animal model.  Furthermore, limited quantitative studies assessing 
transplanted cell graft survival have been published.   
We propose to transplant ferumoxytol labeled human neural progenitor cells 
(hNPCs) into the spinal cord of a large animal (porcine) model and track them in vivo 
with clinical MRI.  The use of large animals is considered critical for validating the 
combination of the surgical procedure, device, feasibility of tracking in vivo, and safety 
of the final product for human use.  The size, anatomy, and general vulnerability of the 
porcine spine and spinal cord better models the human.  The surgical process of exposing 
and manipulating the spinal cord as well as closing the wound in the pig is virtually 
indistinguishable from the human.  Consequently, the pig is subject to the same 
fundamental complications including spinal cord injury, epidural hematoma, abscess, and 
CSF leakage.  The devices that we have designed for human surgery fit the porcine spine, 
meeting the FDA requirement that the safety of the device, technique, and cells to be 
tested as a unit. 
The MR tracking, conducted in a clinical 3T scanner, will allow us to assess our 
ability to track stem cell grafts in vivo in a model that is directly translatable to clinical 
trials.  At the conclusion of this study, we will compare the MRI signal in vivo with post-
mortem histological measures of labeled cells. Furthermore, we will directly compare 
survival of ferumoxytol-labeled and unlabeled cell grafts with graft-specific stereological 
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quantification.  The objectives of this study are to: 1) identify the location of transplanted 
cell grafts in vivo with MRI; 2) quantify ferumoxytol-labeled cell graft survival; and 3) 
correlate MR findings, histological measures of Iron deposits and graft survival. 
 
5.3 METHODS 
5.3.1 Experimental Design 
Female Göttingen minipigs were divided into 5 groups according to their survival 
time and transplantation strategy (Table 4).  The pigs received multiple, independent 
grafts of ferumoxytol labeled hNPC-FLow and hNPC-FHigh cells, and unlabeled hNPCs 
(Figure 11).  Cell grafts were transplanted into the pig thoracolumbar spinal cord 
bilaterally.  The volume of each injection was 10 or 25 microliters with a concentration of 
10,000 cells/µL.  Grafts containing two concentrations of iron (hNPC-FLow and hNPC-
FHigh) from the in vitro experiments were compared to control unlabeled hNPCs in the 
same animal.  Inter-graft distances of 4 mm were used.  Each animal received a total of 
12 to 15 injections based on their cohort.  The hNPC-FHigh grafts were transplanted into 
the rostral spinal cord segment, the hNPC grafts into the middle segment, and the hNPC-
FLow grafts into the caudal segment.  The injections aimed to transplant the cell grafts into 
the motor-neuron containing ventral horn of the spinal cord.  Injected segments were 
identified by rostral and caudal 5-0 blue prolene dural stitches to facilitate histological 
graft identification.  Immunosuppression consisted of a monotherapy with Tacrolimus 
(0.025mg/kg, BID, IV).  Animals were switched to Cyclosporine (10mg/kg, BID, oral) 
for immunosuppression after 28 days. 
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Figure 11.  Spinal Cord Transplantation Schematic.  A representative schematic of the 
spinal cord stem cell transplantation strategy is shown.  Individual injections of unlabeled 
hNPC, and ferumoxytol-labeled hNPC-FLow and hNPC-FHigh cell grafts were bilaterally 
transplanted into the porcine spinal cord with a stabilized stereotactic injection system.  
Cohort A (n = 3) received 15 total injections of 2.5 x 105 and 1.0 x 105 cells.  Cohorts B 
(n = 3), C (n = 3), and D (n = 5) received 12 injections of 2.5 x 105 cells.  hNPC-FHigh cell 
grafts were transplanted into the rostral spinal cord segment, unlabeled hNPC grafts into 
the center segment, and hNPC-FLow grafts were transplanted into the caudal segment. 
 
Table 6. Pig Cohorts.  14 female Göttingen minipigs were enrolled in the study and 
divided into 4 cohorts.  The pigs received pre-operative MRI and serial MRI after 
surgical transplantation of hNPCs into the spinal cord.   
 
Cohorts N of animals MRI 
(Post-Operative Day) 
Survival 
(Days) 
A 3 0, 14 14 
B 3 0, 14, 28 28 
C 3 0, 14, 28, 42 42 
D 5 0, 14, 42, 63, 84, 105 105 
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5.3.2 Intrajugular Catheter Placement 
Before the spinal incision, the neck of the pig was prepped and draped.  The 
internal jugular was exposed surgically and cannulated with a central catheter, which was 
secured with a 3-0 silk tie.  The proximal end of the internal jugular was ligated with a 3-
0 silk tie.  The catheter was then tunneled out of the neck skin dorsally and secured with 
3-0 nylon stitches.  The wound was irrigated and closed with a running 3-0 nylon stitch.  
The catheter was used to administer all IV medication for the duration of the 
experiments. 
 
5.3.3 Thoracolumbar Transplantation 
Pigs were placed in the prone position, with appropriate draping of the operative 
area.  An approximately 10-15 cm incision was performed over the spine and a multi-
level laminectomy was performed over the thoracolumbar spinal cord.  Following 
laminectomy, the percutaneous posts were placed through 1 cm skin incisions above and 
below the primary incision.  The upper and lower posts were mounted to lamina above 
and below the primary incision through small percutaneous incisions.  The microinjection 
platform was attached to the four posts, allowing the device to span the laminectomy.  At 
this point, a 2-4 cm incision was made into the dura mater, allowing exposure of the 
spinal cord.  The dura mater was then tacked away using 4.0 nurulon suture.  At this 
point, the microinjection device was placed and adjusted.  Targeting to the area of interest 
within the spinal cord was achieved with the use of coordinate-based microinjection and 
visual observation.  The injections followed placement of the cannula.  Immediately prior 
to this, a bolus of Methylprednisolone (125mg, Intravenous) was given in an attempt to 
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prevent spinal cord swelling.  A custom infusion cannula of narrow diameter was used.  
For each injection, the appropriate volume of cell suspension was infused by a 
microprocessor-controlled syringe pump at the rate of 5 microliters per minute.  The 
needle was left in place for an additional 1 minute to prevent cell reflux up the cannula 
injection tract before extraction.  Following needle removal, the stereotaxic apparatus 
was relocated to the next target site, separated by 4 mm as necessary to avoid visible 
blood vessels on the dorsal surface of the spinal cord. This process was repeated as 
proposed for each cohort. Once all injections were made, the injection apparatus was 
removed and the incisions were closed in four layers.  The dura was closed using a 4.0 
nurulon stitch, in a watertight fashion.  A 0 vicryl suture was used for the deep muscular 
layer.  The second layer, fascia, was also closed using 0 vicryl suture in a watertight 
fashion.  The dermal layer was closed with 2.0 ethylon, with a running stitch. 
 
5.3.4 Post-Operative Assessment 
Animals underwent a general neurological examination/observation before 
surgery and following complete recovery from the procedure.  Behavioral assessment of 
spinal cord function was performed daily during the 14 first post-operative days and then 
2 times per week until euthanasia.  Sensory evaluation took place in the form of a tactile 
stimulus to the perianal region.  Also, all four limbs were assessed.  This stimulus is not 
noxious or painful but allows assessment of both sensation and motor function in 
response to limb retraction from a steadily applied force (withdrawal response to a 
mechanical stimulus).  Gait and motor function was assessed according to the Tarlov 
scale. This scale provides objective criteria by which to evaluate ability to ambulate as a 
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surrogate measure of motor function.  The score is as follows: (0) no voluntary limb 
function; (1) only perceptible joint movement; (2) active movement but unable to stand; 
(3) to be able to stand but unable to walk; (4) complete normal hind-limb motor function. 
 
5.3.5 In Vivo Magnetic Resonance Imaging 
Pig MRI was performed on a Siemens Trio Trim 3T Full Body MR Scanner with 
a table-integrated spine matrix coil.  Pigs were sedated with ketamine (35 mgs/kg, IM) 
and acepromazine (0.8 mgs/kg, IM), and maintained with isofluorane inhalation (1 – 2%).  
Pigs were placed in the scanner in the head first supine position.  MRI was acquired as 
outlined in the experimental design.  Structural MR images were obtained using standard 
Sagittal T2-weighted spin echo and Coronal T1-weighted 3D sequences.  For grafted cell 
detection, a gradient echo (GRE) T2*-weighted axial sequence sensitive to magnetic field 
inhomogeneities was utilized [multiple echo time = 10 and 16 msec, pulse repetition time 
= 788 msec, average = 4, field of view = 160 x 160 mm, matrix = 512 x 512, and slice 
thickness = 1.5mm)].  The GRE sequence was acquired a second time with a shift of 0.75 
mm to avoid partial volume effects. 
 
5.3.6 Image Analysis 
MR Images of the spinal cord containing cell grafts were analyzed with ImageJ.  
Anatomical position of each graft was determined by observing the distance 
anterior/posterior and left/right from the center of the spinal cord.  Anatomical landmarks 
such as the grey/white junction and location of CSF were also used.  Three blinded expert 
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observers viewed 20 grafts and scored them as on or off target.  On target was defined as 
50% of the graft contacting the ventral horn.  This data was used to determine on/off 
target transplantation using a Chi squared table to generate sensitivity and specificity for 
both hNPC-FLow and hNPC-FHigh grafts.  The volume of the individual grafts was 
calculated using the ImageJ, adapting a previously described method for quantifying 
SPION signal in the rodent brain9.  Briefly, regions of interest in GRE MR images were 
set over half the spinal cord of individual hNPC-FLow and hNPC-FHigh grafts, 
encompassing the entire graft.  Regions of interest over the entire cord were set in areas 
containing control hNPCs.  For these control regions, a value for the average voxel 
intensity minus two standard deviations was calculated.  This value was used as a 
threshold for the regions containing labeled cells.  The number of voxels below the 
threshold was calculated for each graft and was recorded in volume (µL).  Groups were 
compared with ANOVA (p < 0.05 significance) with multiple comparisons (t tests, p < 
0.05). 
 
5.3.7 Euthanasia, Perfusion, and Necropsy 
At endpoints, animals were sedated with ketamine (35 mgs/kg, IM), 
acepromazine (0.8 mgs/kg, IM) and Euthasol (1 ml/10 lbs, IV). Following sedation, 
10,000 USP Units/ml of Heparin Sodium were administered IV five minutes before 
euthanasia, while the heart was still beating.  Transcardiac perfusion with a 0.9% NaCl 
solution followed by a 4% Paraformaldehyde (PFA) solution was then performed to 
improve the quality of the tissue for immunohistochemistry.  A peristaltic pump 
(Masterflex Console Drive pump (model 71-1420) was used for perfusions.  Spinal cords 
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with dura mater intact were harvested by dissection in necropsy.  The cords were placed 
in 4% PFA for 24 hours and then 30% sucrose solution for one week.  The dura mater 
was removed and the region of interested containing cell grafts (marked with prolene 
sutures) was isolated and flash frozen in blocks.  Tissue was then frozen in optimal 
cutting temperature gel and cryosectioned transaxially in 50 micrometer sections.  The 
tissue was placed in cryopreservative for histological analysis. 
 
5.3.8 Histological Staining for Transplanted Human Cells 
An antibody specific to the human nuclear (HuNu) antigen (1:250; Millipore 
MAB1281) was used to determine the location of transplanted cell grafts.  DAB-
enhanced HuNu immunohistochemistry was performed on every 6th section of tissue 
throughout the ROI.  Briefly, Sections were washed in 1X phosphate buffered saline 
(PBS) for 3 x 10 minutes while shaking at room temperature (RT) to remove 
cryoprotectant and thaw. Next, sections were treated with hydrogen peroxide (3% H2O2 
in 1X PBS + 0.1% triton [PBST]) for 15 minutes while shaking at RT. This was 
performed to block endogenous peroxidase activity, reducing non-specific background 
staining in horseradish peroxidase-conjugated antibody steps below. After treatment, 
sections were washed with 1X PBST for 3 x 10 minutes while shaking at RT. Sections 
were then incubated in blocking buffer (5% horse serum in PBST) for 30 minutes while 
shaking at RT. Horse serum was chosen to prevent nonspecific epitope binding of the 
secondary antibody. Once blocked, sections were transferred to anti-human nuclei 
(HuNu) primary antibody reagent (dilution in 2% NGS in 1X PBS) and stored overnight 
on shaker at 4 oC. 
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Tissue sections were washed in 1X PBS for 3 x 10 minutes while shaking at RT. 
Biotinylated horse α mouse antibody was prepared at 1:250 (2% NGS in 1X PBS). 
Sections were incubated in this secondary antibody for 2 hours while shaking at RT. 3 x 
10 minute 1X PBST washes were then performed. Tertiary antibody (ABC kit from 
Vector Labs: [50uL A, 50uL B]/10mL PBST) was prepared 30 minutes prior to use and 
stored while shaking at RT. Following 3 x 1X PBST washes, tissue sections were 
transferred to the tertiary antibody and stored overnight on shaker at 4 oC. 
Tissue sections were then washed in 1X PBS for 3 x 10 minutes while shaking at 
RT. DAB peroxidase substrate was prepared immediately before use, and sections were 
incubated until a dark signal was seen. The maximum recommended DAB incubation 
time is 10 minutes. Tissue sections were then transferred to 1X PBS and washed 
thoroughly for 5 minutes. If Prussian blue costain was desired, sections were kept 
floating and the PB protocol described below was followed. For anti-HuNu staining only, 
sections were transferred to distilled water, mounted onto slides, and allowed to dry 
overnight. Once dry, a cresyl violet background stain was performed, followed by 
dehydration and coverslip. 
 
5.3.9 Stereological Quantification of Engrafted Human Cells 
Stereology constitutes an interdisciplinary field that is largely concerned with the 
three-dimensional interpretation of planar sections of materials or tissues. It uses 
techniques for extracting quantitative information about a three-dimensional material 
from measurements made on two-dimensional planar sections of the material. A random, 
systematic sampling approach is used to provide potentially unbiased and quantitative 
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data and is an important and efficient tool in many applications of microscopy. It may 
thus provide estimates of cell numbers, object size and shape with precision 43,138.  
Briefly, the transplanted area of each individual graft in the spinal cord of every 
pig was sampled using unbiased random uniform sampling. All sections with grafted 
HuNu+ cells were considered for the sample, sections without grafted cells were 
discarded. One out of every six sections was included in the sample for analysis with a 
total distance between sections of 300 µm. A combination of the Cavalieri principle and 
the optical disector was applied to the neuron and grafted cell counting. The equipment 
used for the optical disector included a microscope (Leica DM2500) with a motorized x–
y stage, an electronic microcator (Applied Scientific Instrumentation), which was used 
for measuring movements in the z direction, and the PC software Stereologer™ for cell 
counting. The optical disector frame provided inclusion and exclusion lines to prevent 
edge effects arising from sub-sampling. All grafted cells that came into focus within the 
disector height (15 µm) were counted, provided they did not touch any of the exclusion 
lines and fell in the inclusion lines. The sections were counted with a 60X oil-immersion 
objective (final magnification, 2000X).  Groups were compared with ANOVA (p < 0.05 
significance) with multiple comparisons (t tests, p < 0.05). 
 
5.3.10 Histological Staining for Iron 
Perl’s Prussian Blue (PB) histochemistry was performed at the center and on the 
periphery (600 µm from graft center both rostral and caudal) of all grafts identified with 
HuNu to estimate the amount of iron from ferumoxytol located in each graft.  Briefly, the 
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sections were washed with PBS, incubated with hydrogen peroxide (1%) for 15 minutes, 
washed 3x with distilled water, incubated with Perl’s Prussian Blue reagent (6% HCl + 
2% KFe6CN) for 30 minutes, washed 3x with distilled water, and mounted on glass 
slides.  Eosin background staining was performed and the slides were cover slipped.  
 
5.3.11 Quantification of Histological Iron 
Perl’s Prussian Blue stained grafts were visualized with a Nikon E400 light 
microscope.  Images of the grafts at 4x were acquired under the same exposure 
conditions.  The Perl’s signal was quantified using a threshold technique in ImageJ.  An 
open filter was applied to the entire green and blue channels.  A closed filter was applied 
to peak of the red signal.   This approach negated all signal except that from the 
characteristic blue precipitates.  The total volume of Iron was calculated in microliters per 
graft. Groups were compared with ANOVA (p < 0.05 significance) with multiple 
comparisons (t tests, p < 0.05). 
 
5.3.12 Histological Staining for Human Cell Differentiation 
To assess the differentiation capacity of transplanted, labeled hNPCs, select 
sections containing well-integrated grafts from group D (105 cohort) were stained for the 
presence of human Glial Fibrillary Acidic Protein (GFAP).  Briefly, the sections were 
washed with PBS, incubated in blocking buffer (PBST, 5% goat serum, 5% horse serum), 
and placed directly in a primary mouse antibody anti-human GFAP [1:500, Takara Bio 
STEM123] overnight at 4 °C.  The sections were washed and placed in a secondary 
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antibody goat-anti-mouse 488 (1:1000, A11001, Invitrogen) for one hour at room 
temperature. The coverslips were washed with PBS and mounted in vectashild with 
DAPI.  The slips were visualized with a Nikon E400 Fluorescent microscope.  Images of 
High Power Fields (HPF) at 40x and 100X were acquired.  The presence of human 
GFAP+ cells was qualitatively assessed. 
 
5.3.13 Histological Co-Staining for Human Nuclei and Iron 
Co-staining for human nuclei and iron was performed on select grafts (largest 
engraftment) from each time point.  5 grafts per labeling condition per time point were 
stained in the graft center and periphery.  The immunohistochemical method starts with 
the same method as standard human nuclei staining, but following incubation with DAB 
peroxidase and 1X PBS wash, tissue sections were transferred to distilled water. 3 x 5 
minute distilled water washes were performed on a shaker at RT. The PB reagent (6% 
HCl, 2% KFe6CN at 1:1 dilution) was made under a fume hood immediately prior to use. 
Sections were transferred to the reagent and incubated at 52oC for 20-45 minutes. Next, 
sections were washed for 3 x 5 minutes in distilled water while shaking. Tissue was 
mounted on slides and allowed to dry overnight. Once dry, an eosin background stain was 
performed, followed by dehydration and coverslip. 
 
5.3.14 Immunoperoxidase labeling and tissue preparation for Transmission 
Electron Microscopy 
A section of graft-containing tissue was embedded in wax, sectioned at 50 
nanometers, stained for HuNu, and mounted for analysis with TEM.  Immunoperoxidase 
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labeling was carried out before sample embedding.  Pig spinal cord containing 
transplanted human neural stem cells was fixed with 4% paraformaldehyde in 0.1 M 
phosphate buffer and then stored in cryoprotectant for a period of time before frozen 
sectioning at 50 micrometers.  Frozen sections were then thawed and washed thoroughly 
with 0.1 M PB to get rid of cryoprotectant. For immunoperoxidase labeling, sections 
were first incubated in blocking solution for 30 min at 4°C to minimize non-specific 
labeling.  The blocking solution was phosphate buffered saline (PBS) containing 5% 
normal goat serum (NGS), 5% bovine serum albumin (BSA), and 0.1% cold water fish 
gelatin.  Sections were then incubated in the primary antibody against the human nuclear 
antigen (Millipore MAB1281) diluted with PBS containing 0.1% acetylated BSA (BSA-
c) to 5 µg/ml overnight at 4 degree with gentle agitation. After 6 washes (5 min each) 
with PBS/BSA-c, sections were incubated overnight at 4 degree in biotinylated secondary 
antibody (Vector) at 1:200 dilution.  Following 3 washes with PBS/BSA-c and 3 washes 
with PBS, sections were incubated in avidin-biotin complex from ABC kit (Vector) for 3 
hours and washed again for 6 times with PBS.  Finally, the enzyme reaction was carried.  
Sections were placed in 0.05 M Tris buffer (pH 7.3) containing 0.05% diaminobenzidine 
and 0.003% hydrogen peroxide for 5-10 minutes at room temperature.  Sections were 
then washed, fixed with 2.5% glutaraldehyde in 0.1 M PB and embedded in Eponate 12 
resin.  Ultrathin sections were cut at 70 nanometer thick using a Leica UltraCut S 
ultramicrotome, counterstained with 5% uranyl acetate and 2% lead citrate, and examined 
on an JEOL JEM-1400 transmission electron microscope (Tokyo, Japan) equipped with a 
Gatan 2k x 2k US1000 CCD camera (Pleasanton, CA). 
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5.3.15 Data Analysis 
Individual cell graft-specific information of quantified surviving human cells, 
histological Iron, and MRI volume was compared between individual grafts of the same 
ferumoxytol labeling condition and between conditions.  The primary objectives were to 
correlate the MRI signal with histological iron, cell survival with histological iron, and 
cell survival with MRI.  Linear regression and correlation analysis were done with a one-
sided p value (p < 0.05). 
 
5.4 RESULTS 
5.4.1 Post-Operative Assessment 
Following transplantation, expected post-operative transient morbidity was 
observed (Figure 12).  Transient deficits were observed in the neurological exam, limb 
retraction to applied force, and the Tarlov score.  The animals experienced pain, lethargy, 
and reduced diet immediately following surgery.  However, all animals returned to 
neurologic baseline 7 days after surgery. 
Two animals from group D experienced adverse events related to 
immunosuppression.  The jugular catheter on pig #4 became unusable after post-
operative day (POD) 3 and the animal was switched to oral cyclosporine for the 
remainder of the study.  Pig #3 experienced an adverse reaction to the anesthesia or 
immunosuppression and developed a coagulopathy that required blood transfusion from a 
donor pig on POD 16.  The pig was switched to oral cyclosporine on POD 3 and all 
immunosuppression was discontinued on POD 15.  The pig fully recovered with blood 
transfusion and continued for the duration of the study. 
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Figure 12.  Motor Function Assessed with the Tarlov Scale.  The Tarlov scale was 
used to assess gait and motor function in cohorts A – D that underwent transplantation.  
The score is as follows: (0) no voluntary limb function; (1) only perceptible joint 
movement; (2) active movement but unable to stand; (3) to be able to stand but unable to 
walk; (4) complete normal hind-limb motor function.  Transient morbidity was observed 
in all groups, but all animals returned to baseline after seven days.  Post-Operative Day 
(POD). 
 
5.4.2 Pilot Study and Preliminary Graft Identification of Ferumoxytol-Labeled 
Human Neural Progenitor Cell Grafts in the Porcine Spinal Cord 
To inform long-term pig studies (groups B, C, and D), a short-term pilot study 
with 3 pigs (group A) was conducted using multiple graft sizes per labeling condition.  15 
cell grafts were transplanted into the thoracolumbar spine of the pigs.  Two 25 µL and 
three 10 µL grafts were transplanted per condition (unlabeled hNPC, hNPC-FLow, and 
hNPC-FHigh).  Unlabeled hNPC graft survival was confirmed (100% of grafts identified) 
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with human nuclear antigen staining (HuNu), but the grafts were not visualized with MRI 
or identified with PB staining (Figure 13 A – F).  HNPC-FLow cells grafts were identified 
with HuNu (100% 25 µL, 100% 10 µL) and PB staining.  100% of hNPC-FLow 25 µL, but 
only 67% of 10 µL were identified with MRI (Figure 13 G – L).  HNPC-FHigh cell grafts 
were identified with HuNu, PB, and MRI (100% 25 µL, 100% 10 µL) (Figure 13 M – 
R).  Transplanted cell grafts of 25 µL were used for the remainder of the study based on 
MR visualization and the completion of a dose escalation study by our group44. 
 
5.4.3 In Vivo Visualization and Quantification of Ferumoxytol-labeled Neural 
Progenitor Cell Grafts in the Porcine Spinal Cord with MRI 
Each pig received four 25 µL unlabeled hNPC, hNPC-FLow, and hNPC-FHigh cell 
grafts into the spinal cord with direct injection (Figure 14 C).  The pigs were maintained 
4 (n =3), 6 (n =3), and 15 (n = 5) weeks after transplantation with serial MRI every 2-3 
weeks. Axial GRE T2* images acquired through the transplanted cell graft sites were 
converted to coronal sections using 3D Slicer (Figure 14).  Pre-operative imaging in all 
animals showed normal spinal cord anatomy with no hypointense regions observed in the 
spinal cord.  Two weeks after transplantation, all hNPC-FLow, and hNPC-FHigh cell grafts 
were visualized as hypointense foci with T2*-weighted MRI.  Hypointense foci were not 
observed in the area containing unlabeled cell grafts. 
 
! 81!
 
! 82!
Figure 13.  Preliminary Identification of Ferumoxytol Labeled Cell Grafts in the 
Porcine Spinal Cord.   Representative micrographs and MR images from cohort A (14 
day survival) are shown.  [A – F] Unlabeled hNPC cell grafts of 1.0 x 105 and 2.5 x 105 
cells were not observed with T2*-weighted MRI (C, F) or detected histologically with 
Perl’s Prussian Blue (PB) iron staining (B, E).  The grafts were detected in the spinal 
cord with DAB-enhanced human nuclear antigen staining (black nuclei) (A, D).   
[G - L] Ferumoxytol labeled hNPC-FLow cell grafts of both 1.0 x 105 and 2.5 x 105 were 
identified as multiple black nuclei with human nucleus staining (G, J), as characteristic 
blue precipitates with PB (H, K), and as a hypointense focus (white arrow) with MRI (I, 
L).  [M – R] Ferumoxytol labeled hNPC-FHigh cell grafts of both 1.0 x 105 and 2.5 x 105 
were identified with HuNu (M, P), PB (N, Q), and MRI (O, R).  Scale bars: main panels, 
2 mm; insets, 100 µm. 
 
 
Figure 14: In vivo identification and tracking of ferumoxytol-labeled grafts (Cohort 
C). Pre-operative sagittal T2-weighted (A) and coronal T2*-weighted (B) images 
demonstrate normal spinal cord anatomy and the target site for transplantation. Unlabeled 
hNPCs and ferumoxytol-labeled hNPC-FLow and hNPC-FHigh 2.5 x 105 (25 µL) cell grafts 
were transplanted in to the pig spinal cord bilaterally (C). Hypointense foci, 
representative of hNPC-FLow and hNPC-FHigh labeled cell grafts were observed on post-
operative week 2 (D), 4, (E), and 6 (F) in coronal T2*-weighted images. Unlabeled cell 
grafts were not visualized.  Axial T2* images show individual hypointense foci 
representing ferumoxytol-labeled hNPC-FHigh (G) and hNPC-FLow (I), but not unlabeled 
[0] (H) grafts. 
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Ferumoxytol-labeled cell grafts were quantified using a region of interest and 
minimum threshold in ImageJ (Figure 15 A – N).  The average volume of hNPC-FLow 
and hNPC-FHigh cell graft two weeks after transplantation was 5.3 ± 2.4 µL and 19.6 ± 
5.7 µL, respectively.  A significant decrease in graft volume was observed for both 
hNPC-FLow and hNPC-FHigh cell grafts over time (ANOVA, p < 0.0005) (Figure 15 O – 
Q).  A significant decrease in signal was observed between two and four weeks for the 
hNPC-FLow cell grafts and decreases at later time point was non-significant.  For the 
hNPC-FHigh cell grafts, significant signal decreases were observed between two, four, six, 
and nice weeks after transplantation. 
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Figure 15: In vivo tracking and quantification of ferumoxytol-labeled grafts. A 
representative hNPC-FHigh (A – E) and hNPC-FLow (F – J) cell graft tracked with T2*-
weighted gradient echo MRI from post-operative day (POD) 14 to 105 are shown.  A 
region of interest was created over the unlabeled grafts (K) and a histogram of the voxel 
intensities was calculated using ImageJ (L).  The minimum threshold for the labeled 
grafts was the mean voxel intensity of the unlabeled grafts minus two standard deviations 
to account for the decrease in signal associated with the negative contrast agent 
ferumoxytol.  A representative hNPC-FLow graft is shown (M) with its histogram (N).  
The graft volumes were calculated for all hNPC-FLow (O) and hNPC-FHigh (P) grafts at all 
time points.  Data points are of individual cell grafts and are colored by animal and 
shaped by cohort (cohort B, triangle; C, circle; D, square).   Summary data represented as 
the mean signal intensity at each time point is shown (Q).  Ordinary one-way ANOVA 
and individual unpaired t-tests were performed.  *Significant, P < 0.05; **Significant, P 
< 0.005; ***Significant, P < 0.0005.  hNPC, human neural progenitor cell; F, 
ferumoxytol; POD, Post-Operative Day.  Graphs displayed as mean ± SD. 
 
 
5.4.4 Diagnostic Magnetic Resonance Imaging of Ferumoxytol-Labeled Cell Grafts 
for Predicting On/Off Target Transplantation Site  
 
 
Figure 16.  Representative Micrographs of On and Off Target Cell Grafts.  A 
representative “on target” (A) and “off target” (C) micrograph of a hNPC-FHigh cell graft 
stained for the human nuclear antigen (black nuclei).  On target was defined as greater 
than 50% of the cell graft contacting the motor neuron-containing ventral horn.  T2*-
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weighted MRI showed both an on target (blue arrow) and an off target (red arrow) graft 
in the spinal cord (B).  Scale bars: 1 mm. 
 
Table 7: Contingency table for hNPC-FLow cell grafts.  Sensitivity 86.7%, Specificity 
93.3%.  Data shown from identification of images from three blinded expert observers. 
hNPC-FLow Grafts On Target Off Target 
MRI On Target 13 1 
MRI Off Target 2 14 
 
Table 8: Contingency table for hNPC-FHigh cell grafts.  Sensitivity 86.7%, Specificity 
80.0%.  Data shown from identification of images from three blinded expert observers. 
hNPC-FHigh Grafts On Target Off Target 
MRI On Target 13 3 
MRI Off Target 2 12 
 
To determine the diagnostic capability of ferumoxytol in predicting on and off 
target graft location, T2*-weighted MR images were used to predict on or off target 
(diagnostic test) (Figure 16 B).  The gold standard was histological confirmation of graft 
location with human nuclear antigen staining.  The representative on target graft is 
located in the center of the grey mater of the ventral horn (Figure 16 A).  The 
representative off target graft is located in the ventral lateral white water (Figure 16 C). 
On target was defined as greater than 50% of the cell graft contacting the motor neuron-
containing ventral horn.  Using contingency tables, the utility of identifying 
transplantation location hNPC-FLow and hNPC-FHigh cell graft was assessed.  Using three 
blinded expert observers, T2*-weighted MRI immediately prior to sacrifice of hNPC-
FLow grafts had a sensitivity of 86.7% and specificity of 93.3% in predicting targeting 
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(Table 7).  MRI of hNPC-FHigh cell grafts had a sensitivity of 86.7% and specificity of 
80.0% in predicting targeting (Table 8). 
 
5.4.5 Histological Identification and Quantification of Ferumoxytol-Labeled Grafts 
Pigs were euthanized at the previously described endpoints (Post-Operative Day 
28, 42, or 105) and the spinal cords harvested, sectioned, and stained for Human Nuclear 
antigen (HuNu) with Cresyl violet background stain and Iron with Perl’s Prussian Blue 
(PB) with Eosin background stain.  Representative T2*-weighted axial MR images and 
micrographs for HuNu and PB staining are presented for each cohort.   
In the Post-Operative Day 28 cohort B, all hNPC-FLow and hNPC-FHigh cell grafts 
were identified two weeks after transplantation with an average volume of 4.7 ± 1.5 µL 
and 18.7 ± 7.1 µL, respectively (mean ± standard deviation) and immediately prior to 
sacrifice with a volume of 2.6 ± 1.8 µL and 15.2 ± 6.5 µL, respectively (mean ± standard 
deviation).  Regions containing unlabeled hNPC graft did not contain hypointense foci 
representative of labeled grafts.  These grafts were quantified to have a volume of 0.4 ± 
0.5 µL after transplantation and 0.4 ± 0.7 µL prior to sacrifice.  A significant trend for 
increased MR hypointense signal with increased ferumoxytol dose was observed for all 
groups (ANOVA, P < 0.0005).  Multiple comparison analysis showed a significant 
difference between hNPC-FHigh grafts and control grafts (t test, p < 0.0005), but not 
between hNPC-FLow grafts. 
Stereological quantification of cell survival revealed an average engraftment of 
25.6 ± 3.4 %, 13.4 ± 2.0 %, and 18.8 ± 2.7 % for individual hNPC, hNPC-FLow and 
hNPC-FHigh cell grafts, respectively (mean ± standard deviation).  Engraftment 
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Percentage is defined as the relative percentage of surviving cells quantified with 
stereology compared to the number of cells originally transplanted.  A significant 
increase in survival was observed for hNPC over hNPC-FLow cell grafts (t test, p < 0.05).  
Quantification of histological iron with PB staining and ImageJ minimum threshold 
revealed an average of 0.1 ± 0.2 µL, 2.3 ± 1.4 µL and 7.2 ± 3.0 µL histological iron for 
individual hNPC, hNPC-FLow and hNPC-FHigh cell grafts, respectively (mean ± standard 
deviation) with a statistically significant trend of increasing histological iron with 
ferumoxytol dose (ANOVA, p < 0.0005).   
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Figure 17. Ferumoxytol-labeled grafts identified postmortem (28 day cohort B). A 
representative unlabeled hNPC cell graft six weeks after transplantation was not observed 
with MRI (A) or Perl’s Prussian Blue (Perl’s) Iron staining (C).  It was detected with 
post-mortem human nuclear (HuNu – black) antigen staining (B).  However, both hNPC-
FLow and hNPC-FHigh grafts were observed with MRI (D), (G), HuNu (E), (H), and Perl’s 
(F), (I).  The quantification data is from all 36 grafts in the 28 day survival group (n = 3 
pigs).  Volumetric quantification of MR signal from hNPC, hNPC-FLow and hNPC-FHigh 
cell grafts are shown (J).  Stereological quantification of surviving human nuclei is 
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shown for all groups (K).  Histological Iron quantification was shown for all groups (L).   
Individual data points on figures are color coded by animal.  Scale bars: main panels, 1 
mm; insets, 100 µm; MRI, 2mm.  Ordinary one-way ANOVA and multiple comparison 
unpaired t-tests were performed.  *Significant, P < 0.05; **Significant, P < 0.005; 
***Significant, P < 0.0005.  hNPC, human neural progenitor cell; F, ferumoxytol.  
Graphs displayed as mean ± SD. 
 
In the Post-Operative Day 42 cohort C, all hNPC-FLow and hNPC-FHigh cell grafts 
were identified two weeks after transplantation with a volume of 6.4 ± 3.1 µL and 23.4 ± 
4.9 µL, respectively (mean ± standard deviation).  Immediately prior to sacrifice at POD 
42, 83.3% of hNPC-FLow and 100% of hNPC-FHigh cell grafts were identified with an 
average volume of 2.3 ± 1.5 µL and 14.0 ± 3.0 µL, respectively (mean ± standard 
deviation).  Grafts with a volume of less than 0.5 µL were considered not identified.  A 
statistically significant decrease was observed in both hNPC-FLow and hNPC-FHigh cell 
grafts over time (ANOVA, p < 0.0005).  Stereological quantification of cell survival 
revealed a non-significant difference of average engraftment of 24.0 ± 6.5 %, 17.1 ± 3.9 
%, and 25.0 ± 5.4 % for individual hNPC, hNPC-FLow and hNPC-FHigh cell grafts, 
respectively (ANOVA, p > 0.05).  Quantification of histological iron with PB staining 
and ImageJ minimum threshold revealed an average of 0.1 ± 0.0 µL, 3.1 ± 0.5 µL and 5.0 
± 0.4 µL histological iron for individual hNPC, hNPC-FLow and hNPC-FHigh cell grafts, 
respectively (ANOVA, p < 0.0005). 
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Figure 18. Ferumoxytol-labeled grafts identified postmortem (42 day cohort C). A 
representative unlabeled hNPC cell graft six weeks after transplantation was not observed 
with MRI (A) or Perl’s Prussian Blue (Perl’s) Iron staining (C).  It was detected with 
post-mortem human nuclear (HuNu – black) antigen staining (B).  However, both hNPC-
FLow and hNPC-FHigh grafts were observed with MRI (D), (G), HuNu (E), (H), and Perl’s 
(F), (I).  The quantification data is from all 36 grafts in the 42 day survival group (n = 3 
pigs).  Volumetric quantification of MR signal from hNPC, hNPC-FLow and hNPC-FHigh 
cell grafts are shown (J).  Stereological quantification of surviving human nuclei is 
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shown for all groups (K).  Histological Iron quantification was shown for all groups (L).    
Scale bars: main panels, 1 mm; insets, 100 µm; MRI, 2mm.  Ordinary one-way ANOVA 
and multiple comparison unpaired t-tests were performed.  *Significant, P < 0.05; 
**Significant, P < 0.005; ***Significant, P < 0.0005.  hNPC, human neural progenitor 
cell; F, ferumoxytol.  Graphs displayed as mean ± SD. 
 
 
 
Figure 19. Ferumoxytol-labeled grafts identified postmortem (105 day cohort D). A 
representative T2*-weighted MR image of the region containing a hNPC unlabeled graft 
105 days after transplantation showed no hypointense focus (A).   Representative MR 
images from representative hNPC-FLow (B) and hNPC-FHigh (C) cell grafts showed 
hypointense foci (white arrows) representative of the negative contrast produced by 
ferumoxytol.  The MR signal void volume for all grafts was calculated for the terminal 
time point (D).  Representative micrographs from Prussian Blue iron staining are shown 
for hNPC (E), hNPC-FLow (F) and hNPC-FHigh (G) cell grafts.  Characteristic blue 
precipitates were observed in hNPC-FLow and hNPC-FHigh cell grafts.  Graft-specific 
histological iron was quantified (H).  Representative micrographs of human nuclear 
antigen staining for hNPC (I), hNPC-FLow (J) and hNPC-FHigh (K) cell grafts are shown.  
! 92!
Engraftment was quantified with stereology (I).  Individual data points on figures are 
color coded by animal.  Scale bars: 1 mm; insert, 50 µm.  Ordinary one-way ANOVA and 
multiple comparison unpaired t-tests were performed.  *Significant, P < 0.05; 
**Significant, P < 0.005; ***Significant, P < 0.0005.  hNPC, human neural progenitor 
cell; F, ferumoxytol.  Graphs displayed as mean ± SD. 
 
In the Post-Operative Day 105 cohort, all hNPC-FLow and hNPC-FHigh cell grafts 
were identified two weeks after transplantation with a volume of 5.1 ± 2.1 µL and 17.8 ± 
4.2 µL, respectively (mean ± standard deviation).  Immediately prior to sacrifice at 
POD42, 65.0% of hNPC-FLow and 100% of hNPC-FHigh grafts were identified with an 
average volume of 1.2 ± 1.1 µL and 8.3 ± 4.1 µL, respectively (mean ± standard 
deviation).  Grafts with a volume less than 0.5 µL were not considered identified.  The 
difference in MR signal at POD 105 between hNPC grafts and hNPC-FLow was non-
significant.  Stereological quantification of cell survival revealed an average engraftment 
of 9.6 ± 9.6 %, 12.6 ± 10.9 %, and 14.9 ± 17.7 % for individual hNPC, hNPC-FLow and 
hNPC-FHigh cell grafts, respectively (mean ± standard deviation).  The difference in cell 
survival was non-significant (ANOVA, p > 0.05).  Quantification of histological iron 
with PB staining and ImageJ minimum threshold revealed an average of 0.0 ± 0.0 µL, 2.5 
± 2.9 µL and 5.4 ± 4.6 µL histological iron for hNPC, hNPC-FLow and hNPC-FHigh cell 
grafts, respectively.  One of the hNPC-FLow grafts was excluded form analysis due to a 
histological anomaly that complicated analysis. 
 Further analysis of the stereological quantification of human cell survival revealed 
a significant decrease in survival of unlabeled hNPC cell grafts over time with an average 
engraftment of 25.6 ± 3.4 %, 24.0 ± 6.5 %, and 9.6 ± 2.1 % for POD 28, 42, and 105, 
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respectively (ANOVA, p < 0.005) (Figure 20).  The average survival of hNPC-FLow and 
hNPC-FHigh cell grafts remained relatively constant over time.   
 
 
Figure 20. Quantification of Transplanted Cell Graft Survival with Stereology of 
Human Nuclei. Stereological quantification was done for each individual cell graft in 
each animal for all cohorts.  Engraftment % is defined as the relative percentage of 
surviving human cells compared to the amount originally transplanted.  Ordinary one-
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way ANOVA and multiple comparison unpaired t-tests were performed.  *Significant, P 
< 0.05; **Significant, P < 0.005; ***Significant, P < 0.0005.  hNPC, human neural 
progenitor cell; F, ferumoxytol.  Graphs displayed as mean ± SD. 
 
 
 
Figure 21. Quantification of Histological Iron in Transplanted Cell Grafts. 
Quantification of histological iron was done for each individual cell graft in each animal 
for all cohorts.  Using a threshold method on ImageJ, a volume of histological iron was 
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calculated.  Ordinary one-way ANOVA and multiple comparison unpaired t-tests were 
performed.  *Significant, P < 0.05; **Significant, P < 0.005; ***Significant, P < 0.0005.  
hNPC, human neural progenitor cell; F, ferumoxytol.  Graphs displayed as mean ± SD. 
 
Further analysis of the quantification of transplanted cell graft histological iron 
from the ferumoxytol nanoparticles revealed a significant increase between hNPC, 
hNPC-FLow and hNPC-FHigh cell grafts at all time points (ANOVA, p < 0.005) (Figure 
21).  The average volume of histological iron content remained relatively stable between 
POD 28, 42, and 105 time points for hNPC, hNPC-FLow and hNPC-FHigh cell grafts.   
 
5.4.6 Correlation Analysis of MR Graft Volume, Histological Iron, and Cell Survival 
of Transplanted Ferumoxytol-Labeled Human Neural Progenitor Cell Grafts  
Group analysis revealed a statistically significant difference in change of MRI 
signal between POD 14 and 28 or 42 between rejected and surviving hNPC-FHigh cell 
grafts (Figure 22 A, B).  The hNPC-FHigh cell grafts were grouped by engraftment 
percentage where surviving grafts have over 5% engraftment.  Correlation analysis 
between terminal MR graft volume and graft histological iron revealed a linear 
correlation for hNPC-FHigh cell grafts (r = 0.52, p < 0.0005) (Figure 22 C).  The graft 
volume observed on T2*-weighted MRI was predictive of the amount of ferumoxytol 
nanoparticles in the tissue.  Furthermore, correlation analysis between histological iron 
and % engraftment showed a strong linear correlation for hNPC-FHigh cell grafts (r = 0.63, 
p < 0.0005) conditions (Figure 22 D).  The histological iron observed with PB staining 
was predictive of the survival of the cell graft measured by stereological quantification of 
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surviving human nuclei.  A correlation was not observed between MR graft volume, 
histological iron, or cell engraftment for hNPC-FLow cell grafts. 
 
 
Figure 22. Correlation Analysis of MR Graft Volume, Histological Iron, and Cell 
Survival of Transplanted Human Neural Progenitor Cells for hNPC-FHigh Cell Grafts.  
MR Graft volume is the volume of each transplanted cell graft observed with T2*-weighted 
MRI.  The volume is calculated in µL using a minimum threshold method in ImageJ. 
Histological Iron is the volume of Iron deposits observed in each transplanted cell graft with 
Prussian blue staining.  The volume is calculated in µL using a minimum threshold method 
in ImageJ.  % Engraftment is the relative percentage of surviving human cells in each graft 
compared to the original number injected.  If 100,000 cells were counted in a graft with 
stereology, the % engraftment would be 40% because the number of cells transplanted was 
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250,000 per graft.  Linear regression and correlation analysis were performed with one-tailed 
p tests (p < 0.05).  The p value and r value are reported.  Δ MR signal void volume refers the 
relative percentage change in MR signal calculated between two time points.  “Survived” 
grafts have engraftment over 5% and “rejected” grafts have engraftment below 5%.  
Individual t test and one-way linear regression analysis performed.  *Significant, P < 0.05; 
**Significant, P < 0.005; ***Significant, P < 0.0005.  hNPC, human neural progenitor cell; 
F, ferumoxytol.  Graphs displayed as mean ± SD. 
 
5.4.7 Differentiation of Ferumoxytol-Labeled Cell Grafts In Vivo 
A murine monoclonal antibody specific to human glial fibrillary acid protein was 
used to observe in vivo astrocytic differentiation of transplanted human neural progenitor 
cells of hNPC, hNPC-FLow and hNPC-FHigh cell grafts (Figure 23).  Signal was not observed 
outside of the grafted area in the porcine spinal cord or in completely rejected grafts, 
confirming the signal is from viable human neural progenitor cells and not from host 
astrocytes or rejected cells. 
 
 
Figure 23. Differentiation of Ferumoxytol-Labeled Human Neural Progenitor Cells in 
the Porcine Spinal Cord.  A fluorescent micrograph of a representative hNPC-FHigh cell 
graft is shown at 40X (A) and oil-immersion 100X (B).  A murine monoclonal antibody 
specifically targeted human glial fibrillary acid protein was used and visualized with a 
! 98!
fluorescent secondary antibody (green).  All nuclei are observed with DAPI staining (blue).  
Scale bars: A, 100 µm; B, 50 µm.   
 
5.4.8 Ferumoxytol Particles Remain Internalized by Transplanted Human Neural 
Progenitor Cells 
Transmission Electron Microscopy of tissue sections containing hNPC-FHigh and 
hNPC-FLow cell grafts stained with DAB-enhanced human nuclear antigen staining revealed 
numerous DAB positive human nuclei at post-operative day 42.  The human cells appeared 
healthy with numerous mitochondria and proper cytoarchitecture.  Furthermore, the cells 
were observed to be developing neurites (Figure 24 A).  Importantly, numerous 
nanoparticle-laden endosomes/lysosomes were observed in the cytoplasm (Figure 25 B). 
 
Figure 24: In Vivo Transmission Electron Microscopy. A 50 µm section of a hNPC-FHigh 
cell graft containing tissue was stained with DAB-enhanced HuNu.  The section was 
embedded in resin and sectioned at 50 nm.  Inspection of tissue at low magnification TEM 
(A) revealed numerous DAB-positive nuclei containing cytoplasmic endosomes/lysosomes 
containing nanoparticles observed at high magnification (B).   
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5.4.9 Transplantation of Ferumoxytol-Labeled Human Neural Progenitor Cell Grafts 
into the Spinal Cord Does Not Cause Demyelination of White Mater Tracts 
 
Transplantation of ferumoxytol-labeled cells into the spinal cord does not cause 
demyelination of local white mater tracts as observed with luxol fast blue staining (Figure 
25).  Both non-rejected and rejected grafts show non-myelinated cells in the graft site, but not 
demyelination of local white mater tracts. 
 
 
Figure 25.  Luxol Fast Blue Staining of Myelination Surrounding Transplanted 
Ferumoxytol-Labeled Cell Grafts.   Human nuclear antigen staining of a well integrated, 
non rejected hNPC-FHigh cell graft (A) and of a rejected, inflamed hNPC-FHigh cell graft in the 
white mater (C).  Grafts in the white mater were specifically chosen to look for changes in 
myelination with luxol fast blue staining.  Luxol fast blue staining of contiguous sections for 
the non-rejected (B) and rejected graft (D) showed non-myelinated cells in the graft (pink), 
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but no demyelination of surrounding white mater tracts (blue).  Light microscopy: 10X.  
Scale bars: 1 mm.   
 
5.4 CONCLUSIONS 
Non-invasive imaging modalities, such as MRI, will play a critical role in the 
successful, widespread translation of cellular therapeutics to the Central Nervous System.  
Without imaging, it is impossible to visually observe the transplantation site without an 
invasive surgical procedure or a reliance on stereotactic methods.  Diagnostic monitoring of 
transplanted cellular therapeutics will most likely be required by future clinical trials to 
properly assess delivered dose and long-term safety100.  MRI provides the ability to assess 
graft location, size, migration, host responses, and investigate potential adverse impacts on 
host parenchyma.  The current study provides framework for investigating the use of MRI to 
non-invasively track transplanted stem cells in the CNS of a large animal.  The current study 
was not designed to investigate the therapeutic efficacy of the transplanted cell graft, which 
has been established in previous studies41,64,149.  The objectives of this study were to: 1) 
identify the location of transplanted cell grafts in vivo with MRI; 2) quantify ferumoxytol-
labeled cell graft survival; and 3) correlate MR findings, histological measures of Iron 
deposits and graft survival. 
 Transplantation of unlabeled hNPC, and ferumoxytol-labeled low dose hNPC-FLow 
and high dose hNPC-FHigh cell grafts directly into the spinal cord of pigs was achieved.  The 
transplantation procedure produced expected transient morbidity and all animals returned to 
neurological baseline after one week.  Permanent behavioral or functional deficits were not 
observed.  The animals were followed for different lengths of time, including a “long-term” 
group for 105 days after transplantation.  The purpose of this study was to visualize 
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transplanted hNPCs with MRI and identify them post-mortem, not to optimize dose or assess 
optimal therapeutic benefit.  However, the cells were transplanted to the location that would 
be targeted in a clinical trial for ALS using a clinically approved surgical approach127,128.  A 
pilot study was performed and determined 2.5 x 105 cells per injection as optimal graft size 
for visualization with MRI.  This graft size is in line with previously published clinical 
trials33,70. 
 The transplanted ferumoxytol-labeled grafts were visualized in the spinal cord of the 
pig with clinical 3T MRI.  The graft size was quantified and corresponded with labeling 
condition (low vs. high dose).  Furthermore, the MRI was predictive of histological graft 
location.  After sacrifice, survival of the cell grafts was quantified with stereology and no 
difference in survival was observed between ferumoxytol-labeled and unlabeled control 
grafts.  The change in MR signal can be used to predict graft survival or rejection in hNPC-
FHigh cell grafts.  Histological iron deposits were located within the transplanted cell grafts.  
Correlation analysis showed that MR signal correlated with histological iron and that 
histological iron correlated with graft survival in hNPC-FHigh cell grafts.  It is possible that 
these correlations were not observed in hNPC-FLow cell grafts because of the relatively small 
changes in iron due to the lower initial dose. Furthermore, it was demonstrated the 
ferumoxytol-labeled cell grafts differentiate in vivo, ferumoxytol particles remain in the 
cytoplasm, and that the grafts do not cause damage to local white mater tracts. 
This is the first report to document the ability to monitor SPION-labeled cells in the 
CNS of a large animal model.  While SPION-labeled cells have been tracked in the spinal 
cord of small animal models, these studies were of relatively short duration39.  To the best of 
our knowledge, this is longest report published to date in the spinal cord.  SPION-labeled 
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cells have been tracked for over one year in the brain of small animal models99,107.  The 
spinal cord presents a challenging environment for MRI due to susceptibility artifacts caused 
by interactions between the cerebrospinal fluid, bone, fat, and parenchyma.  Furthermore, 
cardioballistic movement of the spinal cord and local gastrointestinal movement further 
complicate the imaging environment.  
The primary objective was to assess the utility of ferumoxytol labeling as a diagnostic 
marker of transplanted cell graft location and survival.  Importantly, the ferumoxytol labeling 
did not impact cell graft survival.  Furthermore, the T2*-weighted MR images were used to 
predict on and off target grafts with acceptable levels of sensitivity and specificity.  The 
relatively large number of off target grafts could be explained by the use of clinical cannulas 
with depth settings for the human spinal cord, which is slightly larger than the pig.  Most off 
target grafts were located directly ventral to the ventral horn, which would be explained by 
the longer cannulas designed for human use.  The MR images correlated with the amount of 
histological iron in the cell grafts.  The amount of histological iron co-located well with the 
transplanted human cells and correlated with the number of surviving cells.  With this, 
ferumoxytol-labeling is capable of predicting on or off target graft delivery with MRI and 
estimating graft survival with MRI and post-mortem histological analysis in hNPC-FHigh cell 
grafts.  
 Previous groups have reported that transplanted cells do not retain the SPION 
label26,73.  Indeed, iron deposits from SPION were observed outside of transplanted labeled 
cells in rejected grafts.  However, numerous cells retained some level of SPION as observed 
with Transmission Electron Microscopy.   
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CHAPTER 6 
 
 
DEVELOPMENT OF A MAGNETIC RESONANCE IMAGING COMPATIBLE 
SPINAL INJECTION SYSTEM 
(SPECIFIC AIM 3) 
 
 
6.1 INTRODUCTION 
A minimally invasive system for targeted delivery of therapeutics to the human 
spinal cord requires an MRI-compatible injection device.  MRI is the imaging modality 
of choice because of its ability to produce high-resolution images of the spinal cord and 
its ability to visualize cells labeled with SPION.  An injection system with a platform that 
mounts to the spine and contains an injection apparatus that is capable of intra-
parenchymal injections was chosen because of our previous experience with this delivery 
system design for open surgical direct injection studies. 
A computer aided design schematic of the current platform used in open surgical 
procedures shows key features that must be included in the MRI-compatible system 
(Figure 1).  Components of the device include: 
1. Gray components: Surgical retractors and percutaneous pedicle post blocks.  The 
retractors will be eliminated in the MRI-compatible design. 
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2. Blue components: Mounting components and rail system which are attached the 
pedicle post blocks which are fastened to the vertebrae with pedicle screws that will be 
replaced with an MR-compatible version. 
 
3. Green components: Positioning gondola which adjusts position along and across the 
spine (x- and y-directions) that will be replaced with an MR-compatible version. 
 
4. Orange components: Catheter guide system and injection drive (which will be replaced 
by SmartFrame™ system). 
 
5. Figure 2b shows a photo of the device in use during a direct injection surgical 
procedure. 
 
No system currently exists for minimally invasive, targeted intra-parenchymal delivery 
of cellular therapeutics to the human spinal cord.  The current gold standard is injection 
based on naked-eye targeting following a major invasive surgical procedure. 
Additionally, immediate visualization and confirmation of the final cellular graft location 
in vivo is not currently available.  The objective of this study is to develop a minimally 
invasive injection system that allows direct targeting of specific locations within human 
spinal cord parenchyma for delivery of therapeutics and visual confirmation of their 
location using MRI.  A prototype device will be fabricated and the system will be 
assessed in an MR phantom spinal cord model. 
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Figure 26. Surgical Stereotactic Spine-Mounted Injection Platform.  A computer-aid 
design schematic of the current platform used in open surgical spinal cord transplantation 
procedures (A).  A photo of the device in use during a direct injection surgical procedure 
(B). 
 
6.2 METHODS 
6.2.1 Design and Fabrication of the MRI-Compatible Platform 
The MRI compatible platform (blue and green components in Figure 14a) was 
designed to serve many of the same functions as the previous device developed and used 
in the open surgical procedure (Figure 14b), including the ability to rigidly mount to the 
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spine, and the ability to move in the x (medial/lateral) and y (rostral/caudal) planes for 
targeting specific inter-vertebral locations in the spine.  In addition, the platform was 
designed to fasten to the ClearPoint SmartFrame™ injection device developed by MRI 
Interventions Inc (Figure 15).  The platform was designed for fabrication with an MRI-
compatible material that was strong but will not cause any artifacts during imaging.  For 
the MR-compatible platform, polyoxymethylene was chosen for the initial prototypes.  
Polyoxymethylene is a rigid, machineable thermoplastic used in precision parts 
manufacturing when high stiffness and dimensional stability are required55.  The platform 
was designed to maintain a low profile to fit within the bore of the MRI scanner when 
fastened to the animal’s spine, and allow the SmartFrame™ to attach.  Construction of 
the platform occurred at the Emory University Physics machine shop. 
 
 
Figure 27. Overview of ClearPoint System from MRI Interventions.  The 
SmartFrame (A) mounts to the skull on the cranial DBS lead placement applications, but 
will be mounted to the MRI-compatible platform we are developing.  The frame accepts a 
cannula and allows for angular adjustments in the sagittal and coronal planes.  The 
Clearpoint software takes high-resolution T1-weighted images that detect the device 
position in relation to the cranium.  The software and device allows for targeting, 
trajectory planning, and adjustments with near real-time imaging (B).  The entry position 
(which aids in targeting and planning) is determined by a fiducial grid (C) placed on the 
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surface of the skull.  The hand controller (D) allows for regular adjustments while the 
patient is in the scanner.  The device allows a cannula to be passed (E) along the planned 
trajectory and the infusion can be monitored in near real-time (F). 
 
6.2.2 Attachment of SmartFrame™ to the MRI-Compatible Platform  
The SmartFrame™ cannula targeting system from MRI Interventions replaced the 
catheter guidance system and injection drive (orange components in Figure 14a).  The 
SmartFrame™ rigidly fixates to the MRI-compatible platform.  The SmartFrame™ 
attached to the positioning unit of the MRI-compatible platform with mechanical 
mounting hardware that allowed the frame to be rigidly mounted but also removed as 
needed.  The SmartFrame™ device allowed for angular adjustments in the coronal and 
sagittal planes and contained a remote cable drive (SmartFrame™ hand controller) for 
changing these angles from outside the scanner bore. The ClearPoint SmartFrameTM and 
targeting software system is shown in Figure 15. 
The SmartFrame was designed to accommodate a nested dual cannula system 
consisting of an 18 gauge rigid outer cannula and an inner cannula with a 26 gauge 
ceramic needle.  The system used to penetrate the animal and inject into the cord and was 
a modified version of this nesting cannula system used for DBS lead placement.  The 
rigid outer cannula can be advanced manually until penetration of the ligamentum flavum 
then the inner cannula can be connected to the microinjector pump and advanced into the 
spinal cord and for accurate in delivery small volumes72. 
 
6.2.3 Construction of the MRI Phantom Spine Model 
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A human phantom spine model was constructed using Polyvinyl alcohol to mimic 
spinal cord, gum rubber sheet for the ligamenum, doped water for cerebrospinal fluid, 
solid foam for bone, foam for intra-laminal disks, and water for the soft tissue.  The goal 
of choosing these materials is to create a model that has the MR image signal properties 
(T1 and T2) as well as the material properties for developing the injection workflow.  
This model was used to: 1) evaluate the appearance and potential artifacts of the cannula, 
needle, platform, and instruments in the MRI, 2) develop and optimize imaging 
methodology using real-time sequences for visualizing injected cells in the phantom, and 
3) establish workflow for image-guided spinal cord injections. 
 
6.2.4 Magnetic Resonance Imaging 
Pre-procedure imaging was used to determine the location of relevant anatomy 
and cannula trajectory planning.  MR imaging followed established protocols used for 
Deep Brain Stimulator lead placement by using a 3D, T1-weighted turbo spin echo (TSE) 
sequence with 1 x 1 x x 1 mm spatial resolution.  The procedure was performed on a 3T, 
(diameter 50 cm; bore length, 160 cm) clinical MRI scanner (Magnetom Trio Trim, 
Siemens Medical Solutions).  The acquired sequences and the ClearPoint software 
produced three orthogonal image planes for guidance to inter-actively monitor the 
delivery needle position.  Post-delivery imaging of the labeled cells was done using a 
T2*-gradient echo sequence (Chapters 4 and 5) designed to maximize susceptibility-
induced artifacts from the labeled cells. 
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6.3 RESULTS 
6.3.1 Fabrication of a Prototype MRI-Compatible Spine Injection Platform 
 The MRI compatible spine injection platform was fabricated form 
polyoxymethylene at the Emory University Physics Machine Shop.  The device was 
constructed from Computer-Aided Design schematics (Figure 28).  The device was built 
to mount to the spine via percutaneous laminar posts that attached to the platform.  The 
center of the platform contains a positioning unit that can be moved 2 cm in the axial 
plane and 8 cm in the sagittal plane.  This flexibility allows the system to access several 
targets after mounting.  
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Figure 28.  Computed-Aided Design Schematic of Prototype MR-Compatible 
Injection Platform.  The primary features of the platform are shown in the schematic.  
The injection position unit (black arrow) fixates to the ClearPoint SmartFrame system 
and the laminar post holders (black arrowhead) fixate to the posts attached to the spine. 
 
 MRI Interventions provided a custom-built injection system for this study (Figure 
29).  The system includes a ceramic guide cannula and titanium stylet to pass through the 
tissue and provide access to the spinal cord.  The infusion needle is composed of fused 
silica with a stepped tip design and contains long flexible tubing for access in the MR 
scanner. 
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Figure 29. Custom Built Infusion Needle and Guide Cannula.  A custom-built system 
injection cannula system with an infusion needle (black arrowhead) with flexible tubing 
(black arrow), a guide cannula (white arrow), and a stylet (white arrowhead). 
 
6.3.2 Assessment of the MR-Compatible System in a Spine Phantom Model 
 To assess the MR-guided injection system and establish procedural workflow, a 
phantom model of the human spinal cord was employed. 
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Figure 30. Human Spinal Cord Phantom Model.  An image of the spine phantom 
model showing the spinal cord (black arrow) and a MR image of the spine phantom.    
 
The custom built injection needle system was guided through the MRI 
Interventions SmartFrame device attached to the spine platform to the surface of the 
spinal cord using the ClearPoint software.  T2*-weighted imaging showed a large artifact 
from the injection needle and cannula (Figure 31 A Arrow).  The fine tip of the injection 
needle was observed in the phantom spinal cord (Figure 31 A Arrowhead).  An infusion 
of ferumoxytol nanoparticles into the phantom spinal cord revealed a hypointense foci 
representative of SPION nanoparticles (Figure 31 B Arrowhead). 
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Figure 31. MR-Guided Injection of Ferumoxytol Nanoparticles into the Spinal Cord 
Phantom.  Needle insertion prior to injection showed the cannula artifact (arrow) and 
needle inserted into the spinal cord (arrowhead) (A).  After injection, a large hypointense 
foci was observed in the spinal cord (arrowhead) (B). 
 
6.4 CONCLUSIONS 
An MRI- compatible injection system was designed with a prototype spine 
platform, custom-built injection cannulas, and the MRI Interventions ClearPoint system.  
The prototype spine platform was designed and constructed at Emory University.  The 
system was designed to rigidly attach to the spine of a large animal or human subject and 
provide access to the spinal cord through MR guidance.  The custom system was 
successfully tested in a custom-built spine phantom.  Procedural workflow for animal 
studies was established. 
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CHAPTER 7 
 
 
MAGNETIC RESONANCE IMAGING-GUIDED TRANSPLANTATION OF 
NEURAL STEM CELLS INTO THE PORCINE SPINAL CORD: A TECHNICAL 
NOTE* 
(SPECIFIC AIM 3) 
 
 
Purpose: Cell-based therapies are a promising treatment option for traumatic, 
tumorigenic and degenerative diseases of the spinal cord.  Transplantation into the spinal 
cord is achieved with intravascular, intrathecal or direct intraparenchymal injection.  
While the current standard, direct injection is limited by surgical invasiveness, difficulty 
in re-injection, and the inability to directly target anatomic or pathologic landmarks.  The 
objective of this study was to present the proof-of-principle for minimally invasive, 
percutaneous transplantation of stem cells into the spinal cord parenchyma of live 
minipigs under MR-guidance. 
Methods: A MR-compatible spine injection platform was developed to work with the 
ClearPoint SmartFrame system (MRI Interventions, Inc.).  The system was attached to 
the spine of live minipigs and a percutaneous injection cannula was advanced into the 
spinal cord under MR-guidance. 
Results: A cell graft of 2.5x106 neural stem cells labeled with ferumoxytol nanoparticles 
was transplanted into the ventral horn of the spinal cord with MR-guidance.  Graft 
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delivery was visualized with MRI and the grafts were identified in the ventral horn by 
Prussian blue histochemistry.  No post-operative morbidity was observed. 
Conclusion:  This report supports the proof-of-principle for transplantation of 
pharmacologic or biological agents into the spinal cord of a large animal under the 
guidance of MRI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Lamanna JJ, Urquia LN, Hurtig CV, Gutierrez J, Anderson C, Piferi P, Federici T, 
Oshinski JN, and Boulis NM. Minimally Invasive Magnetic Resonance Imaging-Guided 
Transplantation of Magnetic Nanoparticle Labeled Human Neural Stem Cells into the 
Porcine Spinal Cord. Magnetic Resonance in Medicine.   In Review. 
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7.1 INTRODUCTION 
Stem cell-based therapies are under clinical evaluation for the treatment of a range 
of tumorigenic, degenerative and traumatic diseases of the spinal cord, including 
Amyotrophic Lateral Sclerosis (ALS), Spinal Cord Injury (SCI), and Multiple Sclerosis 
(MS).  Intravascular, intrathecal, and intraparenchymal delivery methods have been 
employed in these trials70.  Direct intraparenchymal injection is currently the most 
straightforward, reliable method for transplanting cell therapies directly into the spinal 
cord.  Furthermore, the safety profile of spine-mounted stereotactic platforms capable of 
performing multiple direct injections in to the spinal cord parenchyma following 
laminectomy is established in pre-clinical and clinical studies10,42,53,65,71,89-91,120,125-128. 
Image-guided approaches have been employed in the brain to replace procedures 
traditionally done with stereotactic systems.  The scope and number of MRI-guided 
interventions has advanced in recent years due to hardware and software developments 
that exploit the excellent soft tissue contrast, high spatial resolution, and multi-planar 
imaging capabilities of MRI.  Interventional MRI is the method of choice in many centers 
for guiding implantation of deep brain stimulation (DBS) electrodes23,88,146. 
Moreover, image-guided approaches have been used to access the spine and spinal cord.  
Computed Tomography (CT) and MRI are used in the clinic to guide percutaneous 
cordotomy58,59,94 and other procedures in the spinal cord30,104.   Pre-clinical studies in 
canines employed fluoroscopic guidance to percutaneously transplant stem cells into the 
spinal cord24,75.  Recently, MRI guidance was used to deliver stem cells to the porcine 
intervertebral disc7. 
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The purpose of this study was to establish the proof-of-principle and feasibility of 
MR-guided percutaneous injection of cellular therapeutics into the spinal cord.  MR-
guided direct injection into the spinal cord could allow for transplantation without 
surgical laminectomy and for direct targeting of anatomic or pathologic landmarks in the 
spinal cord.  Furthermore, the reduced invasiveness could improve procedural recovery 
time and allow for re-injection into the same spinal cord segments.  The current study 
was not designed to investigate the therapeutic efficacy or biological properties of 
transplanted cell grafts, which has been established in previous studies41,64,149.  In this 
report, we describe a novel method for minimally invasive delivery of cellular 
therapeutics into the pig spinal cord under the guidance of MRI using a custom-built 
spine mounted platform and the ClearPoint system (MRI Interventions, Inc.).   
 
7.2 MATERIALS AND METHODS 
7.2.1 Ethics Statement 
All procedures were conducted at the Division of Animal Resources in 
accordance with a protocol approved by the Intuitional Animal Care and Use Committee 
at our University. 
 
7.2.2 Cell Preparation 
Human Neural Progenitor cells (hNPCs) isolated from the fetal cortex were 
provided as frozen stocks (Clive Svendsen at Cedars-Sinai Medical Center64,149).  The 
hNPCs were expanded in culture as neurospheres31 and labeled with ferumoxytol, an 
ultra-small superparamagnetic iron oxide nanoparticle (SPIO), previously used for 
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cellular tracking with MRI.  Cells were labeled by incubation with 400 µg/mL of 
ferumoxytol for 7 days18,153.  Immediately prior to surgery, the neurospheres were washed 
and chemically dissociated to single cells.  Pig Neural Progenitor cells (pNPCs) were 
provided as dissociated cells prepared for transplantation (Neuralstem, Inc.) and were 
labeled with SPIO nanoparticles. Cell viability and concentration were assessed with a 
trypan blue exclusion assay (>80% viable required for transplantation).  The hNPCs and 
pNPCs were maintained on ice in hibernation medium until transplantation. 
 
7.2.3 MR-Compatible Injection System 
The prototype injection platform was MRI-compatible and constructed of 
polyoxymethylene resin.  The device was designed to attach to spine laminae rostral and 
caudal to the region of interest with custom-built percutaneous aluminum posts and 
titanium lamina screws (4mm anchor).  The ClearPoint SmartFrame device (MRI 
Interventions, Inc.) was rigidly attached to the injection platform and was maneuvered in 
the rostral/caudal and medial/lateral planes on a rail system (Figure 32A).  The 
SmartFrame allowed for targeting and controlled advancement of the custom-built 
injection needle (MRI Interventions, Inc.) using the ClearPoint targeting software to 
calculate a trajectory.  A ceramic guide cannula with a titanium stylet was used to pass 
through the soft tissues and provide access to the spinal cord.  The infusion needle was 
composed of fused silica and inserted through the guide cannula after stylet removal.  
The internal diameter of the needle tip was 200 µm with a stepped tip design.  When 
inserted through the guide cannula, the infusion needle extended 10.5 mm beyond the tip 
of the cannula, ensuring the guide cannula did not enter the spinal cord parenchyma.  A 
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microprocessor-controlled syringe pump (Tritech Research Inc., Los Angeles, CA) 
attached to the injection needle was used for cell suspension infusion32. 
 
 
Figure 32. In Vitro Assessment of an MR-Compatible Spinal Injection System with 
a Phantom Model.    The MRI compatible injection system (A) utilizes: 1) MR-
Compatible SmartFlow catheter (MRI Interventions), 2) Modified ClearPoint device 
(MRI Interventions), and 3) MR-Compatible spine platform with percutaneous lamina 
posts for fastening to spine.  The system is mounted to a MRI spine phantom model for in 
vitro assessment.  Under the guidance of T1-weighted MRI (3T full-body scanner, 
Siemens) and the ClearPoint software (MRI Interventions), the catheter (arrow) was 
advanced to the surface of the spinal cord in the phantom model (B).  The injection 
needle was inserted into the spinal cord (C) to the planned target (red arrow) and an 
infusion of ferumoxytol iron oxide nanoparticles was performed (dotted arrow), as seen 
with gradient echo T2*-weighted MRI (D). 
 
7.2.4 In Vitro Assessment 
A MR spinal cord phantom model was constructed from a foam spine model and 
an agar gel spinal cord.  The phantom was submerged in water in a clear box (Figure 
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32A).  The MR-compatible injection system was attached to the phantom and multiple 
injections were performed under MR-guidance with the ClearPoint software to establish 
system workflow and targeting. 
 
 
Figure 33.  MR-Guided Transplantation Strategy in the Porcine Spinal Cord.  
Potential cannula trajectories for transplantation of neural stem cells into the spinal cord 
were designed for an animal with a previous laminectomy (solid arrow) and dural 
opening (A, B).  A trajectory (dotted arrow) through the scar tissue (solid arrow) was 
utilized.  A trajectory (dotted arrow) through the interlaminar space was utilized to gain 
access to the cord in a naïve pig with no previous laminectomy (C, D). 
 
7.2.5 Magnetic Resonance Imaging 
All images and procedures were done with a clinical 3T MRI scanner (Magnetom 
TRIO, Siemens Medical, Malvern, PA) with a bore length of 140cm and diameter of 
60cm.  Structural images were acquired using sagittal T2-weighted turbo spin echo (TSE) 
and T1-weighted 3D sequences.  The T1-weighted images were used for fiducial 
identification and trajectory planning.  For cannula visualization and graft identification, 
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a gradient echo (GRE) T2*-weighted axial 2D multi-slice sequence was utilized 
(TE/TR=10/159 msec, Flip Angle=30°, Averages=4, Resolution = 0.9x0.9x1.5 mm). 
 
7.2.6 Anesthesia 
The pigs were fasted for 12 hours prior to induction anesthesia with Ketamine (35 
mg/kg, IM) and Acepromazine (1.1 mg/kg, IM).  The pigs were maintained for the 
duration of the procedure on Isoflurane (1.5 – 2.5%, Inhaled) mixed with oxygen. 
 
7.2.7 In Vivo MR-Guided Spinal Cord Injection 
Two female Göttingen minipigs were enrolled in the study.  The pigs were placed 
in the MRI scanner table in the prone, headfirst position under general anesthesia. 
Appropriate sterile preparation and draping was done over the thoracolumbar spine.  The 
rostral and caudal portions of the injection platform were fastened to the thoracic vertebra 
above and below the target site.  The aluminum posts were advanced to the surface of the 
lamina through a 1 cm dermal incision.  The titanium lamina screws with a 4mm anchor 
were advanced through the posts and fastened into the lamina.  A fiducial grid was placed 
over the skin on the target site (SmartGrid, MRI Interventions, Inc.).  The SmartFrame 
was attached to the injection platform.  Two phased-array body coils were sterile draped 
and placed beside the injection platform.  Pre-entry sagittal T2 2D TSE, sagittal T1 3D, 
and axial T2* GRE 2D images covering the fiducial markers and spinal cord region of 
interest were acquired.  The pre-entry images were imported to the ClearPoint software to 
acquire the target (ventral horn of the spinal cord), plan an initial trajectory, and set the 
cannula entry point on the skin using the fiducial grid.   
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The animal was moved out of the scanner bore and the skin was nicked through 
the fiducial grid to mark the planned entry point and the grid was removed.  Due to the 
thickness of the porcine skin, a 1 cm dermal incision was made over the entry point.  
Stepwise angular and planar adjustments were made with repeat imaging to align the 
cannula with the final planned trajectory in near real-time.  The ceramic guide and stylet 
were advanced to depth at the ligamentum flavum.  The titanium stylet was removed and 
imaging was performed to confirm the cannula was on the correct trajectory.  Once the 
final trajectory was determined to be on target, the injection needle was advanced through 
the cannula and into the spinal cord ventral horn.  Final targeting was assessed with T2* 
GRE imaging.  A single injection of 2.5x106 hNPCs or pNPCs in 25 µL was infused into 
the spinal cord at a rate of 5µL / minute for each animal.  The needle remained in the cord 
for 2 minutes following injection to minimize reflux and repeat GRE imaging was 
performed to confirm cell graft delivery.  The catheter and cannula were removed and 
post-operative scanning was performed. 
 
7.2.8 Post-Operative Management and Behavioral Assessment 
Oral Cyclosporine (10 mg/kg) was administered for immunosuppression from the 
day of surgery to euthanasia.  The pigs underwent general neurological 
examination/observation before and following the procedure. Sensory evaluation took 
place in the form of a tactile stimulus to the interdigital space.  Behavioral assessment of 
motor function was performed daily.  Gait and motor function were assessed according to 
the Tarlov scale125. 
 
7.2.9 Euthanasia, Tissue Processing and Histology 
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The pigs were euthanized 21 days after transplantation.  Transcardiac perfusion 
with 0.9% NaCl solution followed by 4% paraformaldehyde was performed.  The fixed 
spinal cord was excised and frozen.  The cord was sectioned axially at 50 µm intervals 
and stained with Prussian Blue (PB) reagent for microscopic Iron and counter-stained 
with Eosin.  Images were captured with a digital DS-Qi1 high sensitivity cooled CCD 
camera using a Nikon E400 microscope supplied with NIS-Elements imaging software 
(Nikon Instruments, Inc.). 
 
7.3 RESULTS 
7.3.1 In Vitro Assessment 
A spinal cord phantom model was used to establish workflow of the MR-guided 
spinal cord injection system.  The system was mounted to the phantom and T1-weighted 
images (Figure 32B) were used to plan a trajectory to a target in the spinal cord with the 
ClearPoint software.  The injection needle was inserted along the planned trajectory into 
the target in the spinal cord and its position was confirmed with T2*-weighted imaging 
(Figure 32C).  An infusion of ferumoxytol SPIO nanoparticles in 25 µL saline was 
performed and a hypointense focus was observed at the targeted injection site (Figure 
32D).  The infusion cloud encompassed the planned target site in 5/5 injections. 
 
7.3.2 Cell transplantation into the spinal cord under MR guidance 
Two pigs received MR-guided transplantation of cells into the spinal cord.  The 
first pig had a previous two-level thoracolumbar laminectomy including dural opening 
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three weeks earlier to simulate previous surgical transplantation (Figure 33A).  The 
second pig  
 
Figure 34. MR-Compatible Spinal Injection System Placement and 
Targeting/Trajectory Planning In Vivo.  The pigs (n = 2) were sterile prepared in the 
MR scanner and the MRI compatible injection system was securely fastened to the spine 
with percutaneous lamina posts (A).  Two body flex radiofrequency coils were placed on 
either side of the system (B).  A trajectory through the skin and into the ventral horn of 
the spinal cord was calculated with T1-weighted MR images (C) with the ClearPoint 
software to go through the interlaminar space (D) or through scar tissue on a pig with a 
previous laminectomy (not shown). 
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was a naïve pig without previous surgery (Figure 33B).  Percutaneous stem cell injection 
into the spinal cord was initiated through placement of the spine-mounted, MR-
compatible platform attached to the ClearPoint system while the pig was on the MR 
scanner table (Figure 34A). Two phased-array body coils were placed beside the system 
(Figure 34B).  The ventral horn in the spinal cord was targeted using a blend of T2*-
weighted GRE and T1-weighted TSE images.  A trajectory traversing the soft tissue into 
the spinal cord target was selected using the ClearPoint software (Figure 34C).  In the 
naïve pig with no laminectomy, a trajectory through the interlaminar space was utilized 
(Figure 34D).  Successful alignment of the inserted cannula to the planned trajectory was 
confirmed with T2*-weighted MRI after the cannula was advanced to the ligamentum 
flavum (Figure 35A).  The injection needle was inserted into the spinal cord through the 
cannula and placement was confirmed with MRI (Figure 35B, E).  A single graft of 
2.5x106 SPIO-labeled pNPCs (previous laminectomy) or hNPCs (no laminectomy) was 
injected into the cord and a hypointense focus representative of the negative contrast 
produced by the ferumoxytol-labeled graft was observed at the target site in the spinal 
cord with T2*-weighted MRI (Figure 35C, F).  Furthermore, the graft was observed after 
the needle was removed (Figure 35D).  The procedure duration was four hours for the 
pig with laminectomy and six hours in the naïve pig.   
 
7.3.3 Behavioral Assessment 
Pre- and post-operative behavioral assessment was completed.  Following 
recovery from anesthesia, the pigs showed no signs of distress and ambulated within two 
hours.  No deficits were observed in the general neurological exam, sensory evaluation, 
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or motor assessment from the day after surgery.  Post-recovery from anesthesia, both pigs 
received a 4/4 for motor function on the Tarlov scale and withdrew all limbs adequately 
to tactile stimulus.  No deficits were observed over the course of the experiment (21 
days). 
 
 
Figure 35. MR-Guided Spinal Cord Transplantation In Vivo.  Representative T2*-
weighted images from MR-guided spinal cord injection show the SmartFlow catheter 
(arrow) advanced to the surface of the spinal cord (A) in the pig with previous 
laminectomy. The titanium stylet was removed from the ceramic guide cannula and the 
injection needle was inserted into the spinal cord (B).  A graft of 2.5 x 105 pig neural stem 
cells with ferumoxytol nanoparticles was injected into the cord (C).  The needle was 
removed and a hypointense focus (dotted arrow) representative of the graft was observed 
in the cord at the target site (D).  In the animal without laminectomy, the cannula (arrow) 
was guided through the interlaminar space and the injection needle inserted into the cord 
(E).  Once in the cord, a graft of 2.5 x 105 human neural stem cells labeled with 
ferumoxytol nanoparticles was injected.  The graft was observed as a hypointense focus 
on T2*-weighted MRI (F). 
 
7.3.4 Histological Targeting Confirmation 
! 127!
To validate the MR results and confirm the intraspinal location of SPIO-labeled 
cell grafts, the spinal cord was excised and stained for the presence of microscopic iron 
using the Prussian blue reagent.  Characteristic blue precipitates representative of the 
SPIO-labeled cell grafts were located in the ventral horn of the spinal cord in both pigs, 
confirming the MRI findings and delivery of cells into the spinal cord (Figure 36). 
 
 
Figure 36. Histological Confirmation of Graft Delivery into the Spinal Cord.  
Representative light microscopy images of histochemical staining for iron deposits with 
prussian blue reagent.  Characteristic blue precipitates indicative of the ferumoxytol-
labeled cell graft were observed in the ventral horn of the pig with previous laminectomy 
(A, B) and in the central grey mater/ventral horn of the pig with no laminectomy (C, D).  
Scale bars: (A, C) 1 mm; (B, D) 50 µm. 
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7.4 DISCUSSION 
The results of this study provide preliminary evidence for a novel, minimally 
invasive approach aimed at achieving delivery of pharmacologic or biological agents 
directly into spinal cord parenchyma under MRI guidance.  This is the first published 
report of MRI-guided intraspinal stem cell transplantation in a live animal.  Most 
importantly, the use of a large animal model and clinical MRI scanner make this 
procedure directly applicable to clinical translation.  Intraoperative MR targeting, 
trajectory planning and cannula guidance are well established in the brain for the 
implantation of DBS electrodes using the ClearPoint system and sub-millimeter accuracy 
has been achieved72. 
Successful translation of stem cell-based therapies for spinal cord disease requires 
optimization of many parameters, including the delivery method.  The method that 
delivers the most cells to the target site with the least invasive approach would be ideal.  
Ongoing and completed clinical trials have employed intravascular, intrathecal, and 
intraparenchymal delivery approaches to transplant cell therapies to the spinal cord.  
Minimal adverse events, mostly transient sensory deficits, have been observed in these 
trials70.  However, limited evidence exists confirming successful graft delivery, 
engraftment, or survival.  For intrathecal and intravascular approaches, questions remain 
as to how many cells reach the target site. In comparative studies in rodents, 
intraparenchymal approaches have been superior to both intrathecal and intravascular 
approaches in delivering and engrafting cells to the target site111,151.  Intravascular 
approaches require cells to traverse the blood-brain barrier and reach target sites through 
homing mechanisms.  Intrathecal infusion requires cells to traverse the pia mater and 
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penetrate several millimeters of white mater tracts to reach deep grey structures such as 
the ventral horn.  Thus, direct intraparenchymal delivery represents the most 
straightforward approach for delivering cells to the target site.  Optimizing the 
intraparenchymal approach with MR-guidance could allow for increased accuracy with 
direct visualization and targeting of anatomic or pathologic sites in the spinal cord while 
concurrently reducing procedural morbidity. 
The safety profile for intraparenchymal transplantation of cellular therapeutics is 
established in large animal models and clinical trials89-91,120,125-128_ENREF_2.  While MR-
guidance could reduce the need for an open surgical procedure and allow for 
percutaneous delivery, it raises other concerns, including: cerebrospinal fluid leakage or 
hemorrhage of vasculature from incidental needle puncture; inaccurate targeting due to 
displacement of the cord from the resistance of the dura mater to needle puncture; and 
limited range of transplantation sites due to the vertebra.  However, the advantages of this 
approach are: direct targeting to pathology (e.g. SCI lesion), confirmation of needle 
location at target site with MRI, and decreased invasiveness compared to the current 
intraparenchymal delivery procedure.  Furthermore, this approach could allow for repeat 
injection in areas of spinal cord that have been operatively exposed and injected 
previously.  Repeat surgical exposure is challenging due to scar tissue formation, loss of 
tissue planes, and potential adhesion of spinal cord to dura mater.  Extensive preclinical 
studies in large animal models must be conducted to evaluate the safety and accuracy of 
percutaneous, MR-guided spinal cord cell graft transplantation.  The purpose of this study 
was not to investigate the survival, engraftment, or function of the transplanted 
therapeutic product.  A limitation of this report is the use of only two animals for 
! 130!
injection.  However, the main objective was to provide proof-of-principle for this 
procedure. 
7.5 CONCLUSIONS 
We describe the first successful MRI-guided, percutaneous stem cell transplant 
into the spinal cord.   This supports the proof-of-principle for transplantation of stem cells 
into the spinal cord of a large animal under the guidance of MRI.  Additional studies are 
underway to assess the safety and accuracy of the procedure in repeated experiments.  
This MRI-guided, minimally invasive approach could be used clinically to directly 
deliver pharmacologic or biological therapeutics to the spinal cords of patients with ALS, 
SCI lesions, intraspinal tumors, or MS plaques.  
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CHAPTER 8 
 
CONCLUSIONS 
In this thesis, I have described the current state of spinal cord stem cell 
transplantation, with particular regard to delivery methodology and the limited techniques 
available for identifying transplanted cell grafts.  I have also shown how most clinical 
trials transplanting cellular therapeutics to the spinal cord do not have a method for 
identifying/monitoring the transplanted therapy.  Furthermore, these trials rely on surgical 
methods for transplantation.  I described our motivation for developing a diagnostic 
marker for tracking transplanted cell grafts in vivo and post-mortem.  I also described our 
motivation for developing an image-guided, minimally invasive method for spinal cord 
stem cell transplantation.  I discussed the utility of using a clinical grade cell line, an 
FDA approved diagnostic marker, clinical MRI scanner, and a clinically relevant large 
animal (porcine) model in the translation of this approach. 
 From these experiments, I developed a method for labeling human neural 
progenitor cells cultured as neurospheres with ferumoxytol nanoparticle for diagnostic 
tracking with Magnetic Resonance Imaging.  I confirmed the cells internalized the 
ferumoxytol nanoparticles, characterized the labeling efficiency and showed the method 
has limited biological effects. 
 The ferumoxytol-labeled human neural progenitor cells were transplanted into the 
spinal cord of live pigs to assess the utility of ferumoxytol as a diagnostic marker.  The 
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transplantation to did not produce any permanent neurological deficits in the pigs.  The 
transplanted cell grafts were visualized in vivo with MRI and was predictive of graft 
location.  Importantly, the ferumoxytol labeling does not impact cell survival in vivo as 
measured by stereological quantification of cell engraftment.  Correlation analysis 
showed the MR signal correlated with histological iron from ferumoxytol nanoparticles 
and the histological iron correlates with cell survival.  The ferumoxytol labeled cells 
differentiate in vivo.  Together, this suggests the utility of ferumoxytol as a diagnostic 
marker for transplanted human neural progenitor cell grafts in a large animal model.  
 Improving on current delivery systems, I developed a novel method for MRI-
guided spinal cord stem cell transplantation.  I fabricated a MR-compatible spine 
injection platform and worked in collaboration with MRI Interventions Inc. to adapt their 
ClearPoint SmartFrame system to our application.  I developed a workflow and method 
for conducting MRI-guided transplantation and assessed our ability to do so in a phantom 
spinal cord model.  Next, I assessed the utility of our system in a live pig where I 
successfully transplanted ferumoxytol-labeled cells into the spinal cord of a live pig 
through a small dermal incision.  No post-operative deficits were observed and the graft 
was identified in the spinal cord post-mortem.  This was the first MR-guided spinal cord 
injection performed. 
8.1 FUTURE DIRECTIONS 
The next step in utilizing ferumoxytol as a cellular therapeutic diagnostic marker 
in the clinic is to assess efficacy, biodistribution and toxicity in two animal models with 
large cohorts under Good Laboratory Practice conditions. 
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 Developing the MR-guided spinal cord injection system in to a clinical product 
will require additional large animal studies to further refine the procedure and assess 
safety.  A study of five consecutive animals transplanted under the same conditions is 
planned.   
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